Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)
Infections with fungi of the genus ASPERGILLUS.
A fluorinated cytosine analog that is used as an antifungal agent.
A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.
Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
A genus of yeast-like mitosporic Saccharomycetales fungi characterized by producing yeast cells, mycelia, pseudomycelia, and blastophores. It is commonly part of the normal flora of the skin, mouth, intestinal tract, and vagina, but can cause a variety of infections, including CANDIDIASIS; ONYCHOMYCOSIS; vulvovaginal candidiasis (CANDIDIASIS, VULVOVAGINAL), and thrush (see CANDIDIASIS, ORAL). (From Dorland, 28th ed)
Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS.
Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.
Infection in humans and animals caused by any fungus in the order Mucorales (e.g., Absidia, Mucor, Rhizopus etc.) There are many clinical types associated with infection of the central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an opportunistic infection in patients with a chronic debilitating disease, particularly uncontrolled diabetes, or who are receiving immunosuppressive agents. (From Dorland, 28th ed)
Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
Substances that are destructive to protozoans.
A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis).
A species of imperfect fungi from which the antibiotic fumigatin is obtained. Its spores may cause respiratory infection in birds and mammals.
A genus of mitosporic fungi containing about 100 species and eleven different teleomorphs in the family Trichocomaceae.
Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins.
Pulmonary diseases caused by fungal infections, usually through hematogenous spread.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
The ability of fungi to resist or to become tolerant to chemotherapeutic agents, antifungal agents, or antibiotics. This resistance may be acquired through gene mutation.
Meningeal inflammation produced by CRYPTOCOCCUS NEOFORMANS, an encapsulated yeast that tends to infect individuals with ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature HEADACHE; NAUSEA; PHOTOPHOBIA; focal neurologic deficits; SEIZURES; cranial neuropathies; and HYDROCEPHALUS. (From Adams et al., Principles of Neurology, 6th ed, pp721-2)
A nitrogen-free class of lipids present in animal and particularly plant tissues and composed of one mole of glycerol and 1 or 2 moles of phosphatidic acid. Members of this group differ from one another in the nature of the fatty acids released on hydrolysis.
Compounds consisting of a short peptide chain conjugated with an acyl chain.
Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL).
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
A steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result in ERGOCALCIFEROL.
An imidazole antifungal agent that is used topically and by intravenous infusion.
A species of the fungus CRYPTOCOCCUS. Its teleomorph is Filobasidiella neoformans.
Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
Infection with a fungus of the species CRYPTOCOCCUS NEOFORMANS.
Infection in humans and animals caused by fungi in the class Zygomycetes. It includes MUCORMYCOSIS and entomophthoramycosis. The latter is a tropical infection of subcutaneous tissue or paranasal sinuses caused by fungi in the order Entomophthorales. Phycomycosis, closely related to zygomycosis, describes infection with members of Phycomycetes, an obsolete classification.
A genus of zygomycetous fungi of the family Mucoraceae, order MUCORALES, a common saprophyte and facultative parasite of mature fruits and vegetables. It may cause cerebral mycoses in diabetes and cutaneous infection in severely burned patients.
The presence of fungi circulating in the blood. Opportunistic fungal sepsis is seen most often in immunosuppressed patients with severe neutropenia or in postoperative patients with intravenous catheters and usually follows prolonged antibiotic therapy.
A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies.
Infection resulting from inhalation or ingestion of spores of the fungus of the genus HISTOPLASMA, species H. capsulatum. It is worldwide in distribution and particularly common in the midwestern United States. (From Dorland, 27th ed)
An order of zygomycetous fungi, usually saprophytic, causing damage to food in storage, but which may cause respiratory infection or MUCORMYCOSIS in persons suffering from other debilitating diseases.
Hydrocarbons with more than one double bond. They are a reduced form of POLYYNES.
Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically.
A decrease in the number of NEUTROPHILS found in the blood.
N(2)-((1-(N(2)-L-Threonyl)-L-lysyl)-L-prolyl)-L-arginine. A tetrapeptide produced in the spleen by enzymatic cleavage of a leukophilic gamma-globulin. It stimulates the phagocytic activity of blood polymorphonuclear leukocytes and neutrophils in particular. The peptide is located in the Fd fragment of the gamma-globulin molecule.
A mitosporic fungal genus previously called Monosporium. Teleomorphs include PSEUDALLESCHERIA.
Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
A mitosporic fungal genus causing opportunistic infections, endocarditis, fungemia, a hypersensitivity pneumonitis (see TRICHOSPORONOSIS) and white PIEDRA.
MYCOSES of the brain, spinal cord, and meninges which may result in ENCEPHALITIS; MENINGITIS, FUNGAL; MYELITIS; BRAIN ABSCESS; and EPIDURAL ABSCESS. Certain types of fungi may produce disease in immunologically normal hosts, while others are classified as opportunistic pathogens, causing illness primarily in immunocompromised individuals (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME).
Infection with a fungus of the genus COCCIDIOIDES, endemic to the SOUTHWESTERN UNITED STATES. It is sometimes called valley fever but should not be confused with RIFT VALLEY FEVER. Infection is caused by inhalation of airborne, fungal particles known as arthroconidia, a form of FUNGAL SPORES. A primary form is an acute, benign, self-limited respiratory infection. A secondary form is a virulent, severe, chronic, progressive granulomatous disease with systemic involvement. It can be detected by use of COCCIDIOIDIN.
A genus of zygomycetous fungi, family Mucoraceae, order MUCORALES, which sometimes causes infection in humans.
Five membered rings containing a NITROGEN atom.
A fungal infection that may appear in two forms: 1, a primary lesion characterized by the formation of a small cutaneous nodule and small nodules along the lymphatics that may heal within several months; and 2, chronic granulomatous lesions characterized by thick crusts, warty growths, and unusual vascularity and infection in the middle or upper lobes of the lung.
Meningitis caused by fungal agents which may occur as OPPORTUNISTIC INFECTIONS or arise in immunocompetent hosts.
Two-phase systems in which one is uniformly dispersed in another as particles small enough so they cannot be filtered or will not settle out. The dispersing or continuous phase or medium envelops the particles of the discontinuous phase. All three states of matter can form colloids among each other.
The ability of fungi to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutations.
Emulsions of fats or lipids used primarily in parenteral feeding.
A species of MITOSPORIC FUNGI commonly found on the body surface. It causes opportunistic infections especially in immunocompromised patients.
Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.
A species of MITOSPORIC FUNGI that is a major cause of SEPTICEMIA and disseminated CANDIDIASIS, especially in patients with LYMPHOMA; LEUKEMIA; and DIABETES MELLITUS. It is also found as part of the normal human mucocutaneous flora.
A mitosporic fungal genus occasionally causing human diseases such as pulmonary infections, mycotic keratitis, endocarditis, and opportunistic infections. Its teleomorph is BYSSOCHLAMYS.
A chronic progressive subcutaneous infection caused by species of fungi (eumycetoma), or actinomycetes (actinomycetoma). It is characterized by tumefaction, abscesses, and tumor-like granules representing microcolonies of pathogens, such as MADURELLA fungi and bacteria ACTINOMYCETES, with different grain colors.
A species of imperfect fungi which grows on peanuts and other plants and produces the carcinogenic substance aflatoxin. It is also used in the production of the antibiotic flavicin.
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
Superficial infections of the skin or its appendages by any of various fungi.
Enumeration by direct count of viable, isolated bacterial, archaeal, or fungal CELLS or SPORES capable of growth on solid CULTURE MEDIA. The method is used routinely by environmental microbiologists for quantifying organisms in AIR; FOOD; and WATER; by clinicians for measuring patients' microbial load; and in antimicrobial drug testing.
Therapy with two or more separate preparations given for a combined effect.
The action of a drug in promoting or enhancing the effectiveness of another drug.
A mitosporic Tremellales fungal genus whose species usually have a capsule and do not form pseudomycellium. Teleomorphs include Filobasidiella and Fidobasidium.
A parasitic hemoflagellate of the subgenus Leishmania leishmania that infects man and animals and causes visceral leishmaniasis (LEISHMANIASIS, VISCERAL). The sandfly genera Phlebotomus and Lutzomyia are the vectors.
A mitosporic Hypocreales fungal genus, various species of which are important parasitic pathogens of plants and a variety of vertebrates. Teleomorphs include GIBBERELLA.
A mitosporic Onygenales fungal genus causing HISTOPLASMOSIS in humans and animals. Its single species is Histoplasma capsulatum which has two varieties: H. capsulatum var. capsulatum and H. capsulatum var. duboisii. Its teleomorph is AJELLOMYCES capsulatus.
Infection by a variety of fungi, usually through four possible mechanisms: superficial infection producing conjunctivitis, keratitis, or lacrimal obstruction; extension of infection from neighboring structures - skin, paranasal sinuses, nasopharynx; direct introduction during surgery or accidental penetrating trauma; or via the blood or lymphatic routes in patients with underlying mycoses.
Lung infections with the invasive forms of ASPERGILLUS, usually after surgery, transplantation, prolonged NEUTROPENIA or treatment with high-doses of CORTICOSTEROIDS. Invasive pulmonary aspergillosis can progress to CHRONIC NECROTIZING PULMONARY ASPERGILLOSIS or hematogenous spread to other organs.
A mitosporic fungal genus which causes COCCIDIOIDOMYCOSIS.
Ascomycetous fungi, family Microascaceae, order Microascales, commonly found in the soil. They are causative agents of mycetoma, maduromycosis, and other infections in humans.
A large and heterogenous group of fungi whose common characteristic is the absence of a sexual state. Many of the pathogenic fungi in humans belong to this group.
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a choline moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and choline and 2 moles of fatty acids.
Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN.
A species of the fungus CRYPTOCOCCUS. Its teleomorph is Filobasidiella bacillispora.
The sudden sensation of being cold. It may be accompanied by SHIVERING.
Infections of the brain, spinal cord, or meninges by single celled organisms of the former subkingdom known as protozoa. The central nervous system may be the primary or secondary site of protozoal infection. These diseases may occur as OPPORTUNISTIC INFECTIONS or arise in immunocompetent hosts.
The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).
Infections of the respiratory tract with fungi of the genus ASPERGILLUS. Infections may result in allergic reaction (ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS), colonization in pulmonary cavities as fungus balls (MYCETOMA), or lead to invasion of the lung parenchyma (INVASIVE PULMONARY ASPERGILLOSIS).
Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.
Steroids with a hydroxyl group at C-3 and most of the skeleton of cholestane. Additional carbon atoms may be present in the side chain. (IUPAC Steroid Nomenclature, 1987)
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.
Hypersensitivity reaction (ALLERGIC REACTION) to fungus ASPERGILLUS in an individual with long-standing BRONCHIAL ASTHMA. It is characterized by pulmonary infiltrates, EOSINOPHILIA, elevated serum IMMUNOGLOBULIN E, and skin reactivity to Aspergillus antigen.
A complex of polyene antibiotics obtained from Streptomyces filipinensis. Filipin III alters membrane function by interfering with membrane sterols, inhibits mitochondrial respiration, and is proposed as an antifungal agent. Filipins I, II, and IV are less important.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.
Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
An abnormal elevation of body temperature, usually as a result of a pathologic process.
A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
A species of parasitic protozoa having both an ameboid and flagellate stage in its life cycle. Infection with this pathogen produces PRIMARY AMEBIC MENINGOENCEPHALITIS.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Phenomena and pharmaceutics of compounds that inhibit the function of agonists (DRUG AGONISM) and inverse agonists (DRUG INVERSE AGONISM) for a specific receptor. On their own, antagonists produce no effect by themselves to a receptor, and are said to have neither intrinsic activity nor efficacy.
Injections made into a vein for therapeutic or experimental purposes.
Colloids with liquid continuous phase and solid dispersed phase; the term is used loosely also for solid-in-gas (AEROSOLS) and other colloidal systems; water-insoluble drugs may be given as suspensions.
A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.
An inflammatory process involving the brain (ENCEPHALITIS) and meninges (MENINGITIS), most often produced by pathogenic organisms which invade the central nervous system, and occasionally by toxins, autoimmune disorders, and other conditions.
A genus of achlorophyllic algae in the family Chlorellaceae, and closely related to CHLORELLA. It is found in decayed matter; WATER; SEWAGE; and SOIL; and produces cutaneous and disseminated infections in various VERTEBRATES including humans.
The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.
Any technique by which an unknown color is evaluated in terms of standard colors. The technique may be visual, photoelectric, or indirect by means of spectrophotometry. It is used in chemistry and physics. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
The study of the structure, growth, function, genetics, and reproduction of fungi, and MYCOSES.
Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)

Lung weight parallels disease severity in experimental coccidioidomycosis. (1/2502)

Evidence provided by histopathological study of lesions is a valuable adjunct for evaluating chemotherapeutic efficacy in experimental animal models, In addition, this should be correlated with a measure of disease severity in the same animal. The latter could be obtained by homogenization of infected organs and quantitative enumeration of viable cells of the etiological agent, but this would preclude histopathological studies in the same animal. Progression of disease in pulmonary infection is associated with replacement of air space by fluid, cells, and cellular debris. Therefore, an increase in lung weight should reflect severity of disease. Results with the murine model of coccidioidomycosis demonstrate that increasing lung weight parallels the increasing census of fungus cells in the lungs of both treated and nontreated infected mice. This was supported with evidence obtained from microscopic studies of lesions indicating that specific chemotherapy limited spread of the infection and inhibited multiplication of the fungus in the lung. Therefore, lung weight can be used as a measure of disease severity in the murine model of coccidioidomycosis.  (+info)

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. (2/2502)

In August 1997, AmBisome (liposomal amphotericin B, Nexstar, San Dimas, CA) was the first drug approved for the treatment of visceral leishmaniasis by the U.S. Food and Drug Administration. The growing recognition of emerging and reemerging infections warrants that safe and effective agents to treat such infections be readily available in the United States. The following discussion of the data submitted in support of the New Drug Application for AmBisome for the treatment of visceral leishmaniasis shows the breadth of data from clinical trials that can be appropriate to support approval for drugs to treat tropical diseases.  (+info)

Early mycological treatment failure in AIDS-associated cryptococcal meningitis. (3/2502)

Cryptococcal meningitis causes significant morbidity and mortality in persons with AIDS. Of 236 AIDS patients treated with amphotericin B plus flucytosine, 29 (12%) died within 2 weeks and 62 (26%) died before 10 weeks. Just 129 (55%) of 236 patients were alive with negative cerebrospinal fluid (CSF) cultures at 10 weeks. Multivariate analyses identified that titer of cryptococcal antigen in CSF, serum albumin level, and CD4 cell count, together with dose of amphotericin B, had the strongest joint association with failure to achieve negative CSF cultures by day 14. Among patients with similar CSF cryptococcal antigen titers, CD4 cell counts, and serum albumin levels, the odds of failure at week 10 for those without negative CSF cultures by day 14 was five times that for those with negative CSF cultures by day 14 (odds ratio, 5.0; 95% confidence interval, 2.2-10.9). Prognosis is dismal for patients with AIDS-related cryptococcal meningitis. Multivariate analyses identified three components that, along with initial treatment, have the strongest joint association with early outcome. Clearly, more effective initial therapy and patient management strategies that address immune function and nutritional status are needed to improve outcomes of this disease.  (+info)

Systemic candidiasis with candida vasculitis due to Candida kruzei in a patient with acute myeloid leukaemia. (4/2502)

Candida kruzei-related systemic infections are increasing in frequency, particularly in patients receiving prophylaxis with antifungal triazoles. A Caucasian male with newly diagnosed acute myeloid leukaemia (AML M1) developed severe and persistent fever associated with a micropustular eruption scattered over the trunk and limbs during induction chemotherapy. Blood cultures grew Candida kruzei, and biopsies of the skin lesions revealed a candida vasculitis. He responded to high doses of liposomal amphotericin B and was discharged well from hospital.  (+info)

In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. (5/2502)

We evaluated the in vitro and in vivo potencies of a new lipid nanosphere that incorporates amphotericin B (AmB), NS-718, against Aspergillus fumigatus. The in vitro activity of NS-718 (the MIC at which 90% of strains are inhibited [MIC90], 0.25 microgram/ml) against 18 isolates of A. fumigatus was similar to that of deoxycholate AmB (D-AmB; Fungizone; MIC90, 0.25 microgram/ml), but NS-718 was more potent than liposomal AmB (L-AmB; AmBi-some; MIC90, 1.0 microgram/ml). The in vivo efficacy of NS-718 in a rat model of invasive pulmonary aspergillosis was compared with those of D-AmB and L-AmB. A low dose (1 mg/kg of body weight) of L-AmB was ineffective (survival rate, 0%), although equivalent doses of D-AmB and NS-718 were more effective (survival rate, 17%). However, a higher dose of NS-718 (3 mg/kg) was more effective (survival rate, 100%) than equivalent doses of D-AmB and L-AmB (survival rate, 0%). To explain these differences, pharmacokinetic studies showed higher concentrations of AmB in the plasma of rats treated with NS-718 than in the plasma of those treated with D-AmB. Our results suggest that NS-718, a new preparation of AmB, is a promising antifungal agent with activity against pulmonary aspergillosis.  (+info)

Effect of fasting on temporal variation in the nephrotoxicity of amphotericin B in rats. (6/2502)

Evidence for temporal variation in the nephrotoxicity of amphotericin B was recently reported in experimental animals. The role of food in these variations was determined by studying the effect of a short fasting period on the temporal variation in the renal toxicity of amphotericin B. Twenty-eight normally fed and 28 fasted female Sprague-Dawley rats were used. Food was available ad libitum to the fed rats, while the fasted animals were fasted 12 h before and 24 h after amphotericin B injection to minimize stress for the animals. Water was available ad libitum to both groups of rats, which were maintained on a 14-h light, 10-h dark regimen (light on at 0600 h). Renal toxicity was determined by comparing the levels of excretion of renal enzyme and the serum creatinine and blood urea nitrogen (BUN) levels at the time of the maximal (0700 h) or the minimal (1900 h) nephrotoxicity after the intraperitoneal administration of a single dose of dextrose (5%; control group) or amphotericin B (50 mg/kg of body weight; treated group) to the rats. The nephrotoxicities obtained after amphotericin B administration at both times of day were compared to the nephrotoxicities observed for time-matched controls. In fed animals, the 24-h urinary excretion of N-acetyl-beta-D-glucosaminidase and beta-galactosidase was significantly higher when amphotericin B was injected at 0700 and 1900 h. The excretion of these two enzymes was reduced significantly (P < 0.05) in fasting rats, and this effect was larger at 0700 h (P < 0.05) than at 1900 h. The serum creatinine level was also significantly higher (P < 0.05) in fed animals treated at 0700 h than in fed animals treated at 1900 h. Fasting reduced significantly (P < 0.05) the increase in the serum creatinine level, and this effect was larger in the animals treated at 0700 h. Similar data were obtained for BUN levels. Amphotericin B accumulation was significantly higher (P < 0.05) in the renal cortexes of fed rats than in those of fasted animals, but there was no difference according to the time of injection. These results demonstrated that fasting reduces the nephrotoxicity of amphotericin B and that food availability is of crucial importance in the temporal variation in the renal toxicity of amphotericin B in rats.  (+info)

Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. (7/2502)

The present study shows that a number of basic antifungal peptides, including human salivary histatin 5, a designed histatin analog designated dhvar4, and a peptide from frog skin, PGLa, are active against amphotericin B-resistant Candida albicans, Candida krusei, and Aspergillus fumigatus strains and against a fluconazole-resistant Candida glabrata isolate.  (+info)

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. (8/2502)

The in-vitro fungistatic and fungicidal activities of voriconazole were compared with those of itraconazole and amphotericin B. MICs for 110 isolates belonging to 11 species of filamentous fungi were determined by a broth microdilution adaptation of the method recommended by the National Committee for Clinical Laboratory Standards. Minimum lethal concentrations (MLCs) of the three antifungal agents were also determined. The MIC ranges of the three compounds were comparable for Aspergillus flavus, Aspergillus fumigatus, Cladophialophora bantiana and Exophiala dermatitidis. Voriconazole and itraconazole were more active than amphotericin B against Fonsecaea pedrosoi, but the two azole agents were less active against Sporothrix schenckii. Voriconazole was more active than itraconazole or amphotericin B against Scedosporium apiospermum, but less active than the other two agents against two mucoraceous moulds, Absidia corymbifera and Rhizopus arrhizus. Voriconazole and amphotericin B were more active than itraconazole against Fusarium solani. With the exception of S. apiospermum, all the moulds tested had MLC50 values of < or =2 mg/L and MLC90 values of < or =4 mg/L against amphotericin B. Voriconazole and itraconazole showed fungicidal effects against five of the 1 1 moulds tested (A. flavus, A. fumigatus, C. bantiana, E. dermatitidis and F. pedrosoi) with MLC90 values of < or =2 mg/L. In addition, voriconazole was fungicidal for Phialophora parasitica. Our results suggest that voriconazole could be effective against a wide range of mould infections in humans.  (+info)

Disseminated Candidainfections are becoming increasingly common among infants in intensive care nurseries. Although the treatment of choice has traditionally been amphotericin B, some infants experience nephrotoxicity during treatment, which compromises their ability to complete the treatment. Others fail to respond to conventional doses of amphotericin B and may not tolerate increased doses. Some infants have underlying renal disease or are given other nephrotoxic drugs that can potentiate the nephrotoxicity of amphotericin B.. Although three lipid based amphotericin B products are available in many countries, to date there are few data on their safety and efficacy in neonates. Amphotericin B lipid complex (ABLC) is licensed in the United States for the treatment of invasive fungal infections in adults and children who are refractory to or intolerant of conventional amphotericin B. ABLC is less nephrotoxic at higher concentrations than amphotericin B in animal models and humans.1 An effective ...
C. lusitaniae is considered an opportunistic organism whose association with invasive infection has increased in recent years (1, 2, 3, 5, 16). Unlike Candida albicans, which is rarely resistant to amphotericin B, C. lusitaniae has consistently been associated with the failure of amphotericin B treatment in patients with invasive disease (3, 10, 14, 15). Resistance may be innate or may develop during treatment.. Here we report the first clinical case of C. lusitaniae developing amphotericin B resistance during amphotericin B treatment and exhibiting an accompanying difference in colony color on CAC between susceptible and resistant strains. The antifungal susceptibility tests performed according to the NCCLS M-27A macrobroth method by a reference laboratory showed a fourfold increase of the amphotericin B MIC for the isolate recovered after 7 weeks of amphotericin B treatment compared to that for an isolate recovered prior to amphotericin B treatment. The MIC of 1.0 μg/ml reported for the ...
Liposomal Amphotericin B Injection 50 mg, Liposomal Amphotericin B Injection IP 50 mg by UNITED BIOTECH (P) LTD. a manufacturer, supplier, exporter of Liposomal Amphotericin B Injection, Amphotericin B Injection. Call Now.
To assess the mortality and resource utilization that results from acute renal failure associated with amphotericin B therapy, 707 adult admissions in which parenteral amphotericin B therapy was given were studied at a tertiary-care hospital. Main outcome measures were mortality, length of stay, and costs; we controlled for potential confounders, including age, sex, insurance status, baseline creatinine level, length of stay before beginning amphotericin B therapy, and severity of illness. Among 707 admissions, there were 212 episodes (30%) of acute renal failure. When renal failure developed, the mortality rate was much higher: 54% versus 16% (adjusted odds of death, 6.6). When acute renal failure occurred, the mean adjusted increase in length of stay was 8.2 days, and the adjusted total cost was $29,823. Although residual confounding exists despite adjustment, the increases in resource utilization that we found are large and the associated mortality is high when acute renal failure occurs ...
Both intrinsic and acquired resistance to amphotericin B have been documented for Candida lusitaniae. Amphotericin B remains the drug of choice for many critical fungal infections, and the detection of resistance is essential to monitor treatment effectively. The limitations of the National Committee for Clinical Laboratory Standards (NCCLS) reference methodology for detection of amphotericin B resistance are well documented, and several alternative methods have been proposed. Etest assays with RPMI and antibiotic medium 3 (AM3) agar were compared to the NCCLS M27-A broth macrodilution method using AM3 for amphotericin B resistance testing with 49 clinical isolates of C. lusitaniae. The panel included nine isolates with known or presumed resistance to amphotericin B on the basis of in vivo and/or in vitro data. The distribution of amphotericin B MICs by Etest with RPMI ranged from 0.032 to 16 μg/ml and was bimodal. All of the putatively resistant isolates were inhibited by amphotericin B at ...
Amphotericin B powder / Amphotericin B supplier / Amphotericin B manufacturer / Amphotericin B buyer (Pets & Animals - Pet Services)
0196] Throughout this application, various publications are referenced, specifically including those listed below. All such references are incorporated herein by reference. [0197] Brajtburg, J., W. G. Powderly, G. S. Kobayashi and G. Medoff. 1990. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 34:183-188. [0198] Cagnoni, P. J., T. J. Walsh, M. M. Prendergast, D. Bodensteiner, S. Hiemenz, R. N. Greenberg, C. A. Arndt, M. Schuster, N. Seibel, V. Yeldandi, and K. B. Tong. 2000. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. 18(12):2476-83. [0199] Chavanet, P., V. Joly, D. Rigaud, J. Bolard, C. Carbon, P. Yeni. Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob. Agents Chemother. 1994;38(5):963-8. [0200] Cleary, J. D., R. L. Nolan, and S. W. Chapman. 1992 Inhibition of interleukin 1 release ...
A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
Cryptococcal meningitis is a life-threatening infectious complication of AIDS. Because relapse after treatment occurs in over 50 percent of cases, chronic maintenance therapy with intravenous (IV) amphotericin B is usually given. However, amphotericin B is not always effective, has toxic effects, and must be given by the intravenous route. Fluconazole is an antifungal agent that can be given orally and has been shown to be effective against cryptococcal infections in animals and against acute CM in a few AIDS patients. Also, the side effects experienced by over 2000 patients or volunteers given fluconazole have seldom been severe enough to require withdrawal of the drug.. Patients accepted in the trial are randomly assigned to fluconazole or amphotericin B. Fluconazole is given orally once a day and amphotericin B is given intravenously once a week. Dosages depend on body weight. Medications may be given with amphotericin B to prevent or reduce discomfort from associated side effects. Patients ...
TY - JOUR. T1 - Generation of suppressor T lymphocytes and monocytes by amphotericin B. AU - Stewart, S. J.. AU - Spagnuolo, P. J.. AU - Ellner, J. J.. PY - 1981. Y1 - 1981. N2 - Amphotericin B, an anti-fungal polyene antibiotic, has profound immunomodulating properties in murine systems. Reports of similar effects in man are few. Amphotericin B 2.0 μg/ml reduced phytohemagglutinin-induced 3H-thymidine incorporation in peripheral blood mononuclear cells from control of 42,905 to 24,183 (experimental CPM minus control CPM) (p3 cells/well, AMB 87 ± 5 x 103 cells/well; p2 production during 18 hr of incubation from baseline 15.1 ± 2.8 ng/106 cells to 59.4 ± 17.8 ng/106 cells (p. AB - Amphotericin B, an anti-fungal polyene antibiotic, has profound immunomodulating properties in murine systems. Reports of similar effects in man are few. Amphotericin B 2.0 μg/ml reduced phytohemagglutinin-induced 3H-thymidine incorporation in peripheral blood mononuclear cells from control of 42,905 to 24,183 ...
Objective: Amphotericin B failure is frequently seen in patients with candidaemia caused by Candida rugosa. We evaluated amphotericin 13, fluconazole, posaconazole and voriconazole as alternative treatments against infection in mice with two isolates of C. rugosa.Methods: Neutropenic mice were inoculated intravenously with C. rugosa. Amphotericin 13, fluconazole, posaconazole and voriconazole were administered for 7 days after infection. Efficacy of the antifungal treatment was assessed by survival and tissue burden of C. rugosa.Results: All of the four drugs significantly prolonged survival over controls. With both isolates, kidney counts were reduced significantly below controls for amphotericin B, fluconazole and posaconazole. However, voriconazole was less effective than the other antifungals.Conclusion: Despite poor clinical response to amphotericin B, in vivo data indicate that amphotericin B increases organ clearance and survival over untreated controls. However, although voriconazole ...
Background. For patients with Indian visceral leishmaniasis, amphotericin B deoxycholate is usually given as 15 alternate-day infusions of 1 mg/kg over 30 days (total dose, 15 mg/kg); daily treatment with 1 mg/kg for 20 days (total dose, 20 mg/kg) is also used. This study was done to address the unsettled therapeutic questions of administration schedule (alternate-day vs. daily administration) and dose (1 vs. 0.75 mg/kg) and to determine whether the duration of amphotericin B treatment in Bihar, India, can be shortened to 15 days.. Methods. To compare alternate-day versus daily administration and 1-mg/kg versus 0.75-mg/kg doses and to determine whether the duration of treatment could be abbreviated, Indian subjects randomly received 15 infusions of 1 mg/kg (group A; 245 patients) or 0.75 mg/kg (group B; 244 patients) on alternate days or 1 mg/kg (group C; 500 patients) or 0.75 mg/kg (group D; 496 patients) daily. Noninferiority testing compared 6-month cure rates using a 5% margin.. Results. ...
Studies on Amphotericin B. Current Formulations and problems and where we fit in!. Scott C. Hartsel Chemistry Department University of Wisconsin-Eau Claire. Overview. An ominous threat What is Amphotericin B? The problem with Amphotericin B What are liposomes and what good are they?...
Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia Stable (no update expected for reasons given in Whats new) answers are found in the Cochrane Abstracts powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
Detailed Amphotericin B Lipid Complex dosage information for adults and children. Includes dosages for Candidemia, Fungal Infection - Disseminated, Aspergillosis - Invasive and more; plus renal, liver and dialysis adjustments.
Sprawdź ile zapłacisz za lek amphotericin b lipid complex Intravenous, Injection w aptece, znajdź tańsze zamienniki leku. Określ swoje uprawnienia i sprawdź jakie zniżki Ci przysługują.
TY - JOUR. T1 - Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis. AU - Tugume, L.. AU - Morawski, Bm. AU - Abassi, M.. AU - Bahr, Nc. AU - Kiggundu, R.. AU - Nabeta, Hw. AU - Hullsiek, Kh. AU - Taseera, K.. AU - Musubire, Ak. AU - Schutz, C.. AU - Muzoora, C.. AU - Williams, Da. AU - Rolfes, Ma. AU - Meintjes, G.. AU - Rhein, J.. AU - Meya, Db. AU - Boulware, Dr. N1 - Funding Information: This work was supported by the National Institute of Neurologic Disorders and Stroke, the National Institute of Allergy and Infectious Disease, and the Fogarty International Center at the National Institutes of Health (U01AI089244, R01NS086312, T32AI055433 and R25TW-009345). The authors wish to thank Drs Paul Bohjanen and Andrew Kambugu for support and input. We also thank Dr Ali El Bireer and the laboratory staff at Makerere University Johns Hopkins University Laboratory in Kampala as well as Mr Richard Kwizera for ...
Amphotericin B is an antifungal medication that fights infections caused by fungus. Amphotericin B is used to treat serious, life-threatening fungal infections. It is not for use in treating a minor fungal infection such as a yeast infection of the mouth, esophagus, or vagina. Amphotericin B may also be used for...
TY - JOUR. T1 - Candida parapsilosis infection of total hip-joint replacement. T2 - Successful reimplantation after treatment with amphotericin B and 5-fluorocytosine. A case report. AU - Younkin, S.. AU - McCollister Evarts, C.. AU - Steigbigel, R. T.. PY - 1984. Y1 - 1984. N2 - A patient with a Candida parapsilosis infection about a prosthetic total hip joint was successfully managed by removing the prosthetic components and bone cement, administering amphotericin B and 5-fluorocytosine, and replacing the total hip joint fourteen months later. The joint was functioning well without evidence of infection two years after replacement.. AB - A patient with a Candida parapsilosis infection about a prosthetic total hip joint was successfully managed by removing the prosthetic components and bone cement, administering amphotericin B and 5-fluorocytosine, and replacing the total hip joint fourteen months later. The joint was functioning well without evidence of infection two years after ...
The increased use of liposomal amphotericin B (L-AMB) in neonates has occurred without evidence of increased efficacy or safety, results of a retrospective analysis presented at IDWeek 2013.
Title: Amphotericin B: From Derivatives to Covalent Targeted Conjugates. VOLUME: 9 ISSUE: 11. Author(s):Milos Sedlak. Affiliation:Department of Organic Chemistry&Technology, Faculty of Chemical Technology, University of Pardubice, Studentska 573, CZ- 532 10 Pardubice, The Czech Republic.. Keywords:Amphotericin B, antimycotics, systemic mycosis, poly(ethylene glycol), polysaccharides, drug targeting, pHsensitivity, β-glucosidase-sensitivity. Abstract: This mini-review summarizes the development of the derivatives and conjugates of Amphotericin B (AMB) which have not been clinically applied so far but are therapeutically promising. Effects of chemical modifications of AMB upon biological activities of the resulting derivatives are discussed. The examples presented include variation of functional groups in AMB, covalent conjugates with other molecules, poly(ethylene glycols) and polysaccharides. Possibilities of targeted delivery of AMB are discussed. ...
Visceral Leishmaniasis, which is progressive and fatal if not treated, is an insidious, chronic disease that is characterized by irregular fever, anorexia, weight loss, cough, gross enlargement of the spleen and liver, mild anemia and emaciation. This may be preceded by rigors and vomiting. If untreated, Kala-azar, which is the most severe form of Leishmaniasis, has a mortality rate of nearly 100%.. The goal of the project is to establish that a single dose of AMPHOMUL® can be used to achieve a Definitive cure for Visceral Leishmaniasis leading to a short course therapy. The project will also seek to establish that AMPHOMUL ® is safe, at least as effective and more affordable than current treatment, and is without the risk of drug resistance.. The trial is a Prospective, Multicentric, Randomized, Two Arm, Open label Phase III study to Assess Efficacy and Safety of Infusion of Amphomul® (Amphotericin B Emulsion) as Compared to Liposomal Amphotericin B in Patients of Visceral Leishmaniasis ...
In vitro pharmacokinetic/pharmacodynamic data of liposomal amphotericin B (L-AMB) were compared with animal data from neutropenic and nonneutropenic models of azole-susceptible and azole-resistant invasive aspergillosis. L-AMB was equally effective. The in vitro fCmax (maximum concentration of free drug)/MIC ratio associated with 50% of maximal activity was 0.31 (0.29 to 0.33), similar to that in neutropenic but not nonneutropenic mice (0.11 [0.06 to 0.20]). Simulation analysis indicated that standard L-AMB doses (1 to 3 mg/kg) are adequate for nonneutropenic patients, but higher doses (7.5 to 10 mg/kg) may be required for neutropenic patients for Aspergillus fumigatus isolates with MICs of 0.5 to 1 mg/liter. ...
Antifungal agents may differ in their fungicidal activities against Aspergillus spp. In order to compare the fungicidal activities of voriconazole and amphotericin B against 40 isolates of Aspergillus fumigatus, A. flavus, and A. terreus, we developed a new microbroth colorimetric method for assessing fungicidal activities and determining minimal fungicidal concentrations (MFCs). This methodology follows the antifungal susceptibility testing reference method M-38A for MIC determination. After drug removal and addition of fresh medium, growth of viable conidia adhering to the bottoms of the microtitration wells was assessed by a colorimetric assay of metabolic activity after 24 h of incubation. The new method was faster (six times), reproducible (92 to 97%), and in agreement with culture-based MFCs (91 to 100%). Differential fungicidal activities of voriconazole and amphotericin B were found among the three Aspergillus species, with A. fumigatus and A. flavus having the lowest (1 and 2 mg/liter, ...
Note: This work was presented in part at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 31 January 2000.. Acknowledgments: The authors thank Deanne Fuller, Dr. Tom Davis, and Ann LeMonte for laboratory work; Estella C. Wheatley for preparation of the manuscript; and Cynthia R. Flanigan for help with the management of the data over the course of the clinical trial.. Grant Support: In part by a grant from the National Institute of Allergy and Infectious Diseases to the Mycoses Study Group (contract NO1-A1-15802) and by a grant from the National Center for Research Resources, General Clinical Research Center (contract MO1-RR02558) to participating centers, and by Gilead Sciences, Inc. (formerly NeXstar Pharmaceuticals).. Requests for Single Reprints: Philip C. Johnson, MD, University of Texas-Houston Medical School, Division of General Medicine, 6431 Fannin, MSB 1.122, Houston, TX 77030; e-mail, [email protected] Current Author Addresses: ...
Surgical resection of the fungus ball and intravenous amphotericin B is the recommended therapy. If zygomycosis is suspected, prompt amphotericin B therapy should be administered due to the rapid spread and mortality rate of the disease. Amphotericin B (which works by damaging the cell walls of the fungi) is usually administered for a further 4-6 weeks after initial therapy begins to ensure eradication of the infection. Posaconazole has been shown to be effective against zygomycosis, perhaps more so than amphotericin B, but has not yet replaced it as the standard of care. After administration the patient must then be admitted to surgery for removal of the fungus ball. The disease must be monitored carefully for any signs of reemergence.[5] Surgical therapy can be very drastic, and in some cases of Rhinocerebral disease removal of infected brain tissue may be required. In some cases surgery may be disfiguring because it may involve removal of the palate, nasal cavity, or eye structures.[3] ...
Based on the enhanced fluorescence of amphotericin B in acid solutions, a quantitative assay for this polyene antibiotic has been developed that is sensitive and linear in the range of 0.1 to 10.0 muM. The binding of amphotericin B to Saccharomyces cerevisiae was assayed under various conditions as the amount bound to cells in a dialysis chamber or after centrifugation. Two types of binding were defined: weak, reversible binding occurred at 0 C or higher temperatures and even in the presence of inhibitors of energy metabolism, whereas strong, irreversible binding did not occur at 0 C and was inhibited when energy metabolism was blocked. Only strong binding was correlated with cell killing. Weak binding probably involves the outer layer of the membrane; strong binding probably requires disruption of hydrophobic regions of the cell membrane.
Preface xvi. Abacacavir (Ziagen) 435. Abacavir + Lamivudine + Dolutegravir (Triumeq) 381. Acyclovir (Zovirax) 442. Adefovir (Hepsera) 187. Albendazole (Albenza) 3. Amikacin (Amikin) 9. Amoxicillan 11. Amoxicillin-Clavulanate (Augmentin, Augmentin 600ES, Augmentin XR) 32. Amphotericin B (Fungizone) 169. Amphotericin B Colloidal Dispersion - ABCD (Amphotec) 13. Amphotericin B Lipid Complex (Abelcet) 1. Ampicillin 15. Ampicillin-Sulbactam (Unasyn) 394. Anidulafungin (Eraxis) 149. Artemether/Lumefantrine (Coartem) 92. Artesunate 27. Atazanavir (Reyataz) 317. Atazanavir + Cobicistat (Evotaz) 152. Atovaquone (Mepron) 240. Atovaquone/Proguanil (Malarone) 230. Azithromycin (Zithromax, Zmax) 437. Aztreonam (Azactam) 40. Bedaquiline (Sirturo) 337. Benznidazole 51. Bithionol (Bitin) 57. Capreomycin (Capastat) 62. Caspofungin (Cancidas) 60. Cefaclor 66. Cefadroxil (Duricef) 135. Cefamandole (Mandol) 232. Cefazolin (Ancef) 18. Cefdinir (Omnicef) 270. Cefditoren Pivoxil (Spectracef) 343. Cefepime (Maxipime) ...
Objectives A suspension for oral use which consists of three non-absorbable antibiotics (amphotericin B, colistin and tobramycin) is often used in clinical practice for the selective decontamination of the digestive tract (SDD) of patients in intensive care. Such a therapy is a preventive tool to minimise the risk of pneumonia and bacteraemia in intubated patients. The administration and the treatment results are controversially discussed. One limiting factor for a unique SDD treatment in the hospitals is a lack of adequate data regarding batch formula and stability for such a formulation. Since no detailed procedures, specifications or stability data are available for manufacturing this formulation there may be discrepancies regarding formulation and stability of suspensions prepared in different pharmacies. The aim of this research was to collect the physicochemical and microbiological stability data of a developed, stable standard formulation under defined storage conditions. The ...
A Double-Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients [Bowden R et al. CID 2002;35:359]: The authors report a multicenter randomized, double-blind trial of Amphotec (ABCD) in a dose of 6 mg/kg/day vs. Amphotericin B in a dose of 1.0-1.5 mg/kg/day for treatment of invasive aspergillosis in 174 patients. The diagnosis was considered proven if there was a compatible clinical illness and detection of aspergillus by stain or culture from a normally sterile site, or proven with histopathology; it was probable if pulmonary with typical clinical and x-ray findings combined with two positive sputum cultures or a positive stain or culture from a BAL. Of the 174 participants, 88 were given ABCD and 86 were given Amphotericin B. Most of the patients had a hematologic malignancy (70%) and/or a bone marrow transplant (42%). Sites of infection included lungs in 66%, sinuses in 15%, and ...
Use Google powered SiteComber to search within various sites for AMPHOTERICIN B. Links to searches for AMPHOTERICIN B can be found here.
iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board. Vancouver, BC, November 13, 2018--iCo Therapeutics (TSXV: ICO), announced the formation of an oral Amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David Denning.
SAN FRANCISCO-Amphotericin B lipid complex may be the treatment of choice for patients with hematogenous or invasive candidiasis, Elias J. Anaissie, MD, said at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Synonyms for amphotericin in Free Thesaurus. Antonyms for amphotericin. 2 words related to amphotericin: antibiotic, antibiotic drug. What are synonyms for amphotericin?
Find information on Amphotericin B (Abelcet, AmBisome) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
NEW ORLEANS-High doses of liposomal amphotericin B are no more effective than low doses in the treatment of invasive aspergillosis in neutropenic patients, European researchers reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy. 1
Amphotericin B modifies the permeability properties of thin lipid membranes formed from solutions containing sheep red cell phospholipids and cholesterol. At 10-6 M amphotericin B, the DC membrane resistance fell from ≈108 to ≈102 ohm-cm2, and the membranes became Cl--, rather than Na+-selective; the permeability coefficients for hydrophilic nonelectrolytes increased in inverse relationship to solute size, and the rate of water flow during osmosis increased 30-fold. These changes may be rationalized by assuming that the interaction of amphotericin B with membrane-bound sterol resulted in the formation of aqueous pores. N-acetylamphotericin B and the methyl ester of N-acetylamphotericin B, but not the smaller ring compounds, filipin, rimocidin, and PA-166, produced comparable permeability changes in identical membranes, and amphotericin B and its derivatives produced similar changes in the properties of membranes formed from phospholipid-free sterol solutions. However, amphotericin B did not ...
In this document, zofran odt price a reference to intravenous amphotericin B without a specific dose or other discussion of form should be taken to be a reference to the general use of any of the preparations of amphotericin B, with the understanding that the clinical experience is greatest with amphotericin B deoxycholate for essentially all forms of candidiasis and classes of patien. Qualora avvengano, siosservano sintomi gastrointestinali e alterazioni dell`equilibrio idro-elettrolitico. Herald scotland alcoholics anonymous quiz alcoholics questions alcoholism alcoholism quiz alcoholism research alcoholism treatment alcohol recovery alcohol tax alcohol treatment alcohol use test Alex Balluff Alice in Chains a life gone awry alkies AllyB aloha alternativess to 12-step Alternatives to AA Alternative to Al-Anon Al Unser Jr Alyssa Forcehimes Amanda Leann Kueht amends amends letter Amway amy borieo Amy Lee Coy Amy Winehouse and Richard C. • Flynn TR, Shanti RM, Levi MH, Adamo AK, Kraut RA, ...
Title:Amphotericin B-Loaded Poly(Lactide)-Poly(Ethylene Glycol)-Blend Nanoparticles: Characterization and In Vitro Efficacy and Toxicity. VOLUME: 9 ISSUE: 5. Author(s):Caroline Danziato Rodrigues, Diani Meza Casa, Luciana Facco Dalmolin, Luciana Erzinger Alves de Camargo, Najeh Maissar Khalil and Rubiana Mara Mainardes. Affiliation:Department of Pharmacy, Universidade Estadual do Centro-Oeste/UNICENTRO, Rua Simeão Camargo Varela de Sá 03, 85040-080 Guarapuava, PR - Brazil.. Keywords:Amphotericin B, drug delivery, hemolysis, in vitro antifungal, polymeric nanoparticles.. Abstract:In this study, we developed poly(lactide)-poly(ethylene glycol) (PLA-PEG) blend nanoparticles with variable molecular PEG weights (2, 10, or 20 kDa) to encapsulate antifungal amphotericin B (AmB) and to evaluate its in vitro efficacy in strains of Candida sp. and in vitro cytotoxicity in human erythrocytes. The nanoparticles were prepared using an emulsification/solvent evaporation technique and were characterized with ...
This medicine is for infusion into a vein. It is usually given by a health care professional in a hospital or clinic setting.. If you get this medicine at home, you will be taught how to prepare and give this medicine. Use exactly as directed. Take your medicine at regular intervals. Do not take your medicine more often than directed.. It is important that you put your used needles and syringes in a special sharps container. Do not put them in a trash can. If you do not have a sharps container, call your pharmacist or healthcare provider to get one.. Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.. ...
Amphotericin B, the first commercially significant antifungal drug, has been available for more than 30 years. This polyene macrolide antifungal agent continues to play a major role in the treatment of systemic fungal infections, despite the introduction of newer agents such as the azoles. Given the …
1 Answer - Posted in: fungizone, amphotericin b - Answer: According to manufacturer it should be used in 24 hours of reconstitution
The ability of Candida albicans to form biofilms and adhere to host tissues and biomaterial surfaces is an important factor in its pathogenesis. One of the main characteristics of biofilms is their resistance to broad-spectrum anti-microbial drugs.In the present study the formation of biofilm by C. albicans from different sources was evaluated. In addition, the minimum biofilm inhibitory concentration (MBIC) for two antifungals was evaluated.In total, 120 isolates of C. albicans from different sources (patients with vaginitis, patients with candiduria, bucal cavity and environmental surfaces) were collected. Biofilm formation was determined by the 96-well micro-titeration plate method. MBIC testing was also performed, using the calorimetric indicator resazurin for amphotericin B and fluconazole.The results indicated that 100% of C. albicans isolates from different sources had the ability to form biofilms in vitro. Amongst these isolates, 83.3% of isolates had the maximum potential (4+) to form biofilms,
TY - JOUR. T1 - Primary treatment of zygomycosis with liposomal amphotericin B. T2 - Analysis of 28 cases. AU - Shoham, Shmuel. AU - Magill, Shelley S.. AU - Merz, William G.. AU - Gonzalez, Corina. AU - Seibel, Nita. AU - Buchanan, Wendy L.. AU - Knudsen, Tena A.. AU - Sarkisova, Tatyana A.. AU - Walsh, Thomas J.. PY - 2010. Y1 - 2010. N2 - Lipid formulations of amphotericin B are increasingly used in lieu of deoxycholate amphotericin B for primary treatment of zygomycosis, but little is known about the efficacy of the former antifungal in treating this fungal disease. We therefore undertook an analysis of a case series of all patients with zygomycosis who received L-AMB for primary antifungal therapy in five major mid-Atlantic medical centers. Among the categories of variables studied were demographics, methods of diagnosis, microbiology, sites of infection, global responses, and survival. The median patient age was 44 years and 71% were male. Immunosuppressive hematological disorders (54%) ...
TY - JOUR. T1 - Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. AU - Guzman-Cottrill, Judith A.. AU - Zheng, Xiaotian. AU - Chadwick, Ellen G.. PY - 2004/11/1. Y1 - 2004/11/1. N2 - Fungal infections caused by Fusarium in the immunocompromised host are highly resistant to all antifungal agents. Fusarium endocarditis is a rare and usually fatal disease. We report an immunocompromised child who survived Fusarium solani endocarditis despite the in vitro resistance of the organism to all available antifungal agents.. AB - Fungal infections caused by Fusarium in the immunocompromised host are highly resistant to all antifungal agents. Fusarium endocarditis is a rare and usually fatal disease. We report an immunocompromised child who survived Fusarium solani endocarditis despite the in vitro resistance of the organism to all available antifungal agents.. KW - Endocarditis. KW - Fungus. KW - Fusarium. UR - ...
TY - JOUR. T1 - Successful treatment with liposomal amphotericin B of an intraabdomianl abscess due to Candida norvegensis associated with a Gore-Tex mesh infection. AU - Nolla-Salas, J. AU - Torres-Rodríguez, JM. AU - Grau, S. AU - Isbert, F. AU - Torrella, T. AU - Riveiro, M. AU - Sitges-Serra, A. PY - 2000/1/1. Y1 - 2000/1/1. M3 - Article. VL - 32. SP - 560. EP - 562. IS - 5. ER - ...
TY - JOUR. T1 - Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis. AU - Italia, Jagdishbhai Laxmanbhai. AU - Kumar, M.N.V Ravi. AU - Carter, Katharine. PY - 2012/8. Y1 - 2012/8. N2 - Leishmaniasis is a protozoan disease, which is responsible for response for major epidemics in many parts of the World. Amphotericin B (AMB) is one of the drugs used to treat leishmaniasis but it must be given intravenously and serious side effects such as nephrotoxicity can limit its use. Development of a formulation of AMB, which can be given by a non-invasive route but is still as effective as the conventional formulation, whilst causing minimal adverse side effects, is required. The present study describes a method for scale up production of a per oral nanoparticle formulation of AMB (AMB-NP) and compared its efficacy both in vitro and in vivo against Leishmania donovavni. Prophylactic studies showed that the AMB-NP formulation was ...
TY - JOUR. T1 - Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. AU - Martino, Rodrigo. AU - Viscoli, Claudio. PY - 2006/1. Y1 - 2006/1. N2 - Persistent or recurrent fever of unexplained origin (PFUO) in neutropenic patients receiving antibiotic therapy is commonly treated with empirical antifungal therapy (EAFT). EAFT was established as an adequate management of PFUO around 20 years ago with conventional amphotericin B deoxycholate (c-AmB), despite its high rate of infusional and systemic toxicities. In recent years, EAFT trials for PFUO have used less toxic agents, such as the lipid formulations of AmB, the new azoles, and the echinocandin, caspofungin. In clinical trials, the lipid formulations of AmB [especially liposomal AmB (L-AmB)] provided similar efficacy with lower toxicity but at a much higher cost. Although rarely used in clinical practice, fluconazole is equivalent to c-AmB, provided patients at high risk of Aspergillus ...
Amphotericin B shows a top adjustment of in vitro activity adjoin abounding breed of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B alignment from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is about absolutely…
CORRESPONDENCE. Responding to the evidence for improved treatment for cryptococcal meningitis in resource-limited settings. To the Editor: The World Health Organization (WHO) issued the first evidence-based treatment guidelines for cryptococcal meningitis in December 2011.1 Although its incidence has decreased with increased access to antiretroviral therapy, cryptococcal meningitis remains a major cause of death in people with HIV/AIDS, with over 500 000 deaths every year in sub-Saharan Africa. It is a leading cause of death in the Médecins sans Frontières (MSF) HIV/AIDS programmes in Africa.2,3. The preferred treatment in the WHO guidelines combines amphotericin B injectable with oral solid formulations of either flucytosine or fluconazole. The liposomal injectable form of amphotericin B is also indicated as an alternative to conventional amphotericin B because it is associated with fewer side-effects. However, it is acknowledged that this option is currently too expensive for routine use in ...
INJECTION, ADENOSINE, 6 MG (NOT TO BE USED TO REPORT ANY ADENOSINE PHOSPHATE INJECTION, ADENOSINE, 90 MG (NOT TO BE USED TO REPORT ANY ADENOSINE PHOSPHATE INJECTION, ADRENALIN, EPINEPHRINE, UP TO 1 ML AMPULE INJECTION, ALATROFLOXACIN MESYLATE, 100 MG INJECTION, METHYLDOPATE HCL, UP TO 250 MG INJECTION, ALPHA 1 - PROTEINASE INHIBITOR - HUMAN, 10 MG INJECTION, AMIODARONE HYDROCHLORIDE, 30 MG INJECTION, AMPHOTERICIN B, ANY LIPID FORMULATION, 50 MG INJECTION, AMPHOTERICIN B LIPID COMPLEX, 10 MG INJECTION, AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX, 10 MG INJECTION, AMPHOTERICIN B LIPOSOME, 10 MG INJECTION, AMPICILLIN SODIUM/SULBACTAM SODIUM, PER 1.5 GM INJECTION, SUCCINYLCHOLINE CHLORIDE, UP TO 20 MG INJECTION, METARAMINOL BITARTRATE, PER 10 MG INJECTION, CHLOROQUINE HYDROCHLORIDE, UP TO 250 MG INJECTION, ATROPINE SULFATE, UP TO 0.3 MG INJECTION, BACLOFEN, 50 MCG FOR INTRATHECAL TRIAL INJECTION, BENZTROPINE MESYLATE, PER 1 MG INJECTION, BETHANECHOL CHLORIDE, MYOTONACHOL OR URECHOLINE, UP TO 5 MG ...
Growth patterns and intracellular Ca2+ concentrations in the mutant strain Aspergillus awamori 66A containing a recombinant aequorin gene were studied in the presence of a permeabilizing fungicidal agent amphotericin B. The cell response, i.e., changes in the growth and development of the fungus (initiation of spore germination, mycelial growth, and intensity of sporulation) was dose-dependent. Low concentrations of amphotericin B (2.5 μM) stimulated spore germination: the number of germinating spores was 2-3 times higher than in the control (without the fungicide). At higher amphotericin concentrations (20 μM) spore germination was inhibited. Amphotericin B had a dose-dependent effect on mycelial growth and sporulation intensity on solid Vogel medium. Intracellular Ca2+ concentrations in the presence of amphotericin B were investigated using the luminescence of the photoprotein aequorin. High concentrations of amphotericin B (10 and 20 μM) were shown to cause an instantaneous increase in Ca2+
den Boer M, Das AK, Akhter F, Burza S, Ramesh V, Ahmed BN, Zijlstra EE, Ritmeijer K, 2018. Safety and effectiveness of short-course AmBisome in the treatment of post-kala-azar dermal leishmaniasis: a prospective cohort study in Bangladesh. Clin Infect Dis 67: 667-675 ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
OBJECTIVES. Pentavalent antimonials, alone or in combination with allopurinol, are the most frequently drugs used in the management of canine leishmaniasis (CL). Despite clinical remission occurs in a majority of cases, most dogs remain parasitologically infected and relapses are frequent. It should be considered that if a clinical but not parasitological cure is achieved, dogs may act as a reservoir of the disease. Moreover, side effects and development of resistances must be considered. Amphotericin B desoxycholate (AmB) is a powerful leishmanicidal agent. Its use in dogs with CL it not very extended, due in part to its nephrotoxicity. Recently the initial effectiveness and toxicity of a new protocol using a lipid emulsion of AmB was assessed.2 The aim of this prospective study is to evaluate both, the initial and the long-term efficacy of this protocol in the treatment of dogs naturally infected with CL. MATERIALS. 14 dogs showing clinical signs of CL and diagnosed after visualization of ...
Current drug regimens for cutaneous leishmaniasis (CL) include toxic systemic therapies such as amphotericin B (AB) and pentavalent antimonials. Fluconazole (FZ) is a well-tolerated potential oral alternative for the management CL. To date, few objective data exist to guide clinical decision-making when selecting a therapeutic agent a priori, and standardized, clinically-approved drug susceptibility testing platforms for Leishmania spp. have yet to be established. The Sensititre™ YeastOne™ YO9 plate is a commercialized drug susceptibility plate including AB and FZ used for routine testing of non-fastidious yeast. Our objective was to adapt the readily available Sensititre™ YeastOne™ YO9 plate, to determine drug susceptibility profiles of AB and FZ in cultured isolates of Old World and New World Leishmania spp. for the treatment of CL. Promastigotes were cultured in Tobies medium with Lockes overlay until log phase growth was achieved, inoculated into the Sensititre™ system, and incubated
Four patients who had recently received kidney transplants became infected with Aspergillus fumigatus while receiving immunosuppressive therapy. Three were shown to have invasive pulmonary mycotic disease, and one of these had documented dissemination. A fourth patient had respiratory symptoms and fever and was found to have mycelial forms consistent with A. fumigatus in his sputum, verified by cultures. All four were effectively treated with amphotericin B in low, widely spaced doses. Early diagnosis was apparently the key to successful management of the invasive Aspergillus fumigatus infection in these patients. Discovery of mycelial forms in fresh preparations of sputa or bronchial washings is a valuable clue to active infections. Securing tissue by biopsy is warranted in those patients who develop a pulmonary infiltrate or cavity that is not otherwise causally explained. ...
ClinicalTrials.gov summary of A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
Logical Images, Inc. d/b/a VisualDx (hereinafter VisualDx, we, us, or our) has created this Acceptable Use Policy, Medical Disclaimer, & Copyright Notice (this Notice) to inform you (hereinafter you, your, or yourself) as a purchaser of a license for and/or user of the software hosted by VisualDx known as VisualDx (the Software) of certain important terms and conditions set forth in the VisualDx End User License Agreement that governs your license for and/or use of the Software (the EULA). This Notice is subject to all of the terms and conditions set forth in the EULA and does not replace or limit it in anyway. You should read the EULA in detail prior to purchasing a license for or using the Software to make sure you understand and agree to its terms and conditions. Nothing in this Notice will (a) expand your rights or VisualDx′s obligations under the EULA or (b) modify or otherwise affect any terms and conditions of the EULA or the rights of the parties under the EULA. In ...
Treatment. From the 417 cases collected, information concerning antifungals used was recorded in 299 (52.5%). Therapy based on a single medication was given to 219 (73.2%) patients while 80 (26.7%) received combined therapy. Deoxycholate amphotericin B was used as single therapy in 106 patients and in 72 of them was followed by different maintenance medications. Itraconazole was prescribed as single therapy in 83 patients or following amphotericin B in 62 patients; it was used with other antifungals in 5 cases. Fluconazole was given in 41 cases as single therapy or in combination. Ketoconazole was prescribed in 8 instances (2.6%) while posaconazole was given as salvage therapy to 2 patients (0.7%).. Discussion Among the endemic mycoses of the Americas the larger number of human cases reported correspond to histoplasmosis (1,3,4,14,15). Despite the fact that the larger endemic areas are those surrounding the Ohio and Mississippi River Valleys of the United States, this mycosis also occurs ...
A stability study of amphotericin B, colistin and tobramycin in a hydrophilic suspension commonly used for selective decontamination of the digestive tract by HPLC and in vitro potency measurements ...
Invasive fungal infections are a significant cause of morbidity and mortality in children. Successful management of these systemic infections requires identification of the causative pathogen, appropriate antifungal selection, and optimisation of its pharmacokinetic and pharmacodynamic properties to maximise its antifungal activity and minimise toxicity and the emergence of resistance. This review highlights salient scientific advancements in paediatric antifungal pharmacotherapies and focuses on pharmacokinetic and pharmacodynamic studies that underpin current clinical decision making. Four classes of drugs are widely used in the treatment of invasive fungal infections in children, including the polyenes, triazoles, pyrimidine analogues and echinocandins. Several lipidic formulations of the polyene amphotericin B have substantially reduced the toxicity associated with the traditional amphotericin B formulation. Monotherapy with the pyrimidine analogue flucytosine rapidly promotes the emergence ...
Guinea pigs (0.4-0.45 kg in weight) were obtained from the Animal Center of the College of Basic Sciences, Jilin University. The use of these animals adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. A strain of A. fumigatus (JLMR054) that was isolated from a patient with fungal endophthalmitis was donated by the Fungal Department of the College of Basic Sciences, Jilin University. Using a 30-gauge needle and a 1.0-mL plastic syringe, 0.02 mL Aspergillus suspension (1.0 × 106 CFU/mL) was injected directly into the vitreous cavity of 30 guinea pigs at the pars plana, approximately 1.5 mm posterior to the limbus. Voriconazole and liposomal Amp-B were supplied in powder form by Livzon Pharmaceutical Group, Inc. (Zhuhai, China) and New Pioneer, Inc. (Shanghai, China), respectively. The powder was suspended in 100% dimethylsulfoxide prior to use. The animals were randomly divided into three groups. Group A (control group) received an intravitreally administered ...
Both these studies also demonstrated that, with appropriate monitoring, conventional amphotericin B is reasonably well tolerated, with drug discontinuations in 3% of patients in the first 2 weeks in the Mycoses Study Group trial [21]. Saline and fluid loading equivalent to 1 litre normal saline daily should be given unless contraindicated, to minimize nephrotoxicity [63], and electrolytes replaced as required. Anaemia, secondary to suppression of erythropoietin transcription [64], is also a predictable side effect of amphotericin B [65-67]. This may be more clinically significant in populations with lower baseline haemoglobin levels, and where transfusion, when occasionally needed, is difficult.. Flucytosine, at the historically low daily dose of 100 mg/kg, was also well tolerated without real-time drug level monitoring in either trial. A substudy of the Thai trial comparing oral and intravenous flucytosine at the same daily dosage of 100 mg/kg has provided some insight into this observation. In ...
Polymeric micelles prepared from a series of poly(ethylene glycol)-poly(lactide) (PEG-PLA) diblock copolymers with various PLA chain lengths were designed as drug carriers for water insoluble drug amphotericin B (AmB). Physicochemical properties of AmB-loaded micelles were evaluated. Micelles were freeze-dried to obtain longtime stable formulations. The redispersibility of the freeze-dried samples was poor when the weight ratio of PLA block was bigger than the PEG block of the copolymer. Various types of lyoprotectants including saccharides and PEGs with different molecular weight were tested to improve the redispersion performance of the freeze-dried samples. PEG was proved to be more effective than saccharides on stabilizing the micelles during lyophilization when the weight ratio of PLA block was bigger than PEG block. The sustained release in vitro of AmB was evidenced. About 80% of AmB was released in 80 h. The in vitro release behavior could be best described by the first-order equation. ...
Also amphotericin B. One of two antifungal antibiotics, the other designated amphotericin A (not used clinically), derived from a strain of Streptomyces nodosus and effective against a wide range of fungi and against some species of Leishmania. It is used intravenously in the treatment of progressive, potentially fatal fungal infections and as a secondary drug in the treatment of mucocutaneous leishmaniasis and topically in the treatment of superficial candidiasis. See also: Antibiotics Antibiotic Glossary Antibiotics (blog) ...
Before the introduction of the antifungal amphotericin B therapy in the mid-1950s for cryptococcal meningitis, the mortality rate was 100% for these cases. Published studies from the USA and Europe indicate that while current treatment regimens are still associated with acute mortality rates during initial therapy, the 12 month survival rates among all patients with maintenance therapy are significantly improved and a large proportion of patients do extremely well on maintenance antifungal therapy.4-6 8-13 The introduction of antiretroviral treatment regimens has further improved morbidity and mortality from fungal infections in AIDS patients in the west.. Our observational study of cryptococcal meningitis in AIDS patients, one of the largest so far from Central Africa, provides further insight into the clinical presentation, natural history, and outcome of this disease in the sub-Saharan African situation. The results of this study substantiates our clinical observations over the past decade at ...
The pericardial fluid that was drained was sent for laboratory analysis, including microbial testing. Cultures were positive for septate mycelia, compatible with a diagnosis of cardiac fungal infection. This, along with the clinical presentation, was diagnostic of a cardiac aspergilloma. Due to rarity of the condition and high degree of fatality associated with the lesion in reported cases in the literature (1-4), the management of the condition posed a dilemma. Surgical resection of the mass and/or direct intralesional injection of amphotericin B were considered as possible approaches but both the ideas were shelved due to fear of spreading the disease to the other uninvolved parts of the myocardium. The final consensus was to initially treat the patient with intravenous amphotericin B with close monitoring of patients condition and to repeat CMRs at regular intervals. A repeat CMR showed no change in the size of the mass, and surgical intervention was once again considered and finally ...
The membrane-active antibiotics amphotericin B and polymyxin B enhanced the action of rifampicin, rifampicin analogs, and tetracycline against macromolecular synthesis and growth of mouse L-cells, human HeLa cells, and KB cells in tissue culture. The specificities of the second agents were maintained in that rifampicin inhibited RNA synthesis and tetracycline inhibited protein synthesis.. ...
Candida species are important nosocomial pathogens; however, little is known about the epidemiology of Candida lusitaniae, an organism frequently resistant to amphotericin B. We evaluated 98 patients admitted to the bone marrow transplant and medical intensive care units of a tertiary-care hospital. Each patient with C. lusitaniae was matched with control patients. Restriction fragment analysis of DNA was used to determine strain relatedness. Seven patients (7.1%) with C. lusitaniae were identified; five acquired C. lusitaniae after admission to the study unit. All isolates were susceptible to amphotericin B. There were no differences between patients and controls with regard to duration of stay in the study unit, antibiotic administration, antifungal therapy, immunosuppressive therapy, catheter use, or underlying disease. Temporal and geographic clustering of five patients with identical strains occurred. No common source was identified. Restriction fragment analysis revealed a total of eight ...
TY - JOUR. T1 - Toward the establishment of standardized in vitro tests for lipid-based formulations, Part 1: Method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. AU - Williams, Hywel David. AU - Sassene, Philip J. AU - Kleberg, Karen. AU - Bakala-NGoma, Jean-Claude. AU - Calderone, Marilyn. AU - Jannin, Vincent. AU - Igonin, Annabel. AU - Partheil, Anette. AU - Marchaud, Delphine. AU - Jule, Eduardo. AU - Vertommen, Jan. AU - Maio, Mario. AU - Blundell, Ross. AU - Benameur, Hassan. AU - Carriere, Frederic. AU - Mullertz, Anette. AU - Porter, Christopher John. AU - Pouton, Colin William. PY - 2012. Y1 - 2012. N2 - The Lipid Formulation Classification System Consortium is an industry-academia collaboration, established to develop standardized in vitro methods for the assessment of lipid-based formulations (LBFs). In this first publication, baseline conditions for the conduct of digestion tests are suggested and a series of eight ...
Introduction. Posaconazole is a triazole antifungal that is used in the treatment of a variety of fungal infections, as well as in the management of mucormycosis (on an off-label basis). Eosinophilia associated with exposure to azole antifungals has been described rarely in the literature. Case presentation. A 31-year-old male on peritoneal dialysis (PD) for end-stage renal disease, secondary to diabetic nephropathy, presented to hospital with abdominal pain after a trip to St Lucia. He was taken to the operating room, where the PD catheter was removed and an abdominal-wall abscess was debrided. R hizopus species was recovered on culture of the abdominal-wall tissue, and the patient was started on amphotericin B deoxycholate. He was subsequently stepped down to posaconazole, for a planned treatment duration of 12 months. Approximately 43 days after the initiation of posaconazole, it was noted that his peripheral eosinophil count started to rise. No other cause for the eosinophilia was identified.
Thus far, no studies have compared directly amphotericin B (AMB) with one of the lipid formulations of AMB for IA. Moreover, it is highly unlikely that such studies will be conducted in the future.. The lipid formulations of AMB have been shown in uncontrolled studies to have an efficacy rate of about 40-60% in IA patients whose disease was refractory to AMB or who were intolerant to it.(10). There is a consensus that the lipid products of AMB result in lower nephrotoxicity and infusion-related toxicity, but the daily acquisition prices are much higher than those of AMB deoxycholate. This nephrotoxicity frequently appears to be clinically significant, especially in the most heavily immunosuppressed patients.(11) Furthermore, a recent pharmacoeconomic analysis of a randomised, double-blind comparative trial of AMB and liposomal AMB in empirical therapy in febrile neutropenic patients showed that nephrotoxicity, which was caused mainly by AMB, increased hospital costs. When modelled in an analysis ...
Over 50 years, AmB, the prototypic representative of membrane-targeting antifungals (9), has been the mainstay for treating clinical invasive fungal infections despite its nephrotoxicity (21). However, its working mechanism remains elusive. Better understanding of how AmB interacts with the cell membrane is essential for guiding future development of novel resistance-refractory and low-toxicity polyene or other antifungals. For decades, AmB has been generally believed to aggregate with ergosterol to from ion channel vertically in the cell membrane, subsequently causing catastrophic membrane curvature and intracellular substances leakage (20). Until recently, a sterol sponge model was proposed to serve as another mechanism (21). As for the lateral orientation of AmB in the sterol sponge model, the paper by Anderson et al. (21) demonstrated that AmB from both surface adsorption model and sterol sponge model likely exist parallel with the membrane surface. In addition, when AmB positions in the ...
Early diagnosis and treatment of cryptococcal chorioretinitis is important. Combination treatment with flucytosine and intravenous amphotericin B is considered the treatment of choice for disseminated... more
IIIPhD, Department of Internal Medicine, Polokwane Mankweng Hospital Complex, University of Limpopo, Polokwane. To the Editor: Cryptococcal meningitis (CM) remains a serious cause of mortality and morbidity in individuals infected with the human immunodeficiency virus (HIV). The optimal treatment of CM is unknown. We conducted a systematic review to determine the best treatment for CM with an emphasis on resource-poor settings. Six studies met the inclusion criteria; none was found that compared amphotericin B with fluconazole. From the available evidence, it is not possible to determine which treatment is superior for CM.. Background. Despite the increasingly wide availability of antiretroviral therapy (ART), CM remains a significant cause of mortality and morbidity among HIV-infected individuals; untreated, its outcome is universally fatal.1 In South Africa, despite the availability in the public sector of antifungal therapy (fluconazole (FLU) and amphotericin B (AmB)) for treating CM, ...
by Rose , 1 Jul, 2017 , Blog, Candida Diet, Children Health, Gut Health, Health Tips, Healthy Tips, Tips , If you have been diagnosed with Candida overgrowth (Candidiasis), your doctor may prescribe Nystatin (Mycostatin or Bio-Statin) and Amphotericin B (Fungizone or Mysteclin-F) anti-fungal medications. Anaphylaxis or allergic reactions may occur while taking Nystatin and Amphotericin B. Please discuss with your doctor if you have had any allergic reaction before. If you are not sure whether you have Candida overgrowth or not, you may try a simple test called The Spit Test (Click here). Bear in mind that the Candida Spit Test is not 100% accurate so if you are in doubt, see your doctor for further testing. Candida can have a serious effect on the gut, brain, heart, liver, kidneys, thyroid, uterus, bladder and lungs. Following the anti-Candida diet and treatment help killing off the Candida and restore the balance of gut flora. Anti-Candida Herbal Tea Ingredients Agrimony - 1 part (Buy ...
Amphotericin[edit]. Amphotericin B, introduced in 1957, remains the treatment of choice for severe infections. It is usually ... In a case report of a 23-year-old Black male with HIV and coccidioidal meningitis, combination therapy of amphotericin B and ... In very severe cases, combination therapy with amphotericin B and an azole have been postulated, although no trials have been ... It can be administered either in the classic amphotericin B deoxycholate formulation or as a lipid formulation. No studies have ...
Amphotericin B. This antifungal medication is delivered intravenously. Many patients, however, cannot tolerate Amphotericin B ... Lipid formulations of amphotericin B are usually recommended instead of amphotericin B deoxycholate because of a better adverse ... Amphotericin B can be used for severe infection during pregnancy. For children with disseminated or severe disease, ... In case of sporotrichosis meningitis, the patient may be given a combination of Amphotericin B and 5-fluorocytosine/Flucytosine ...
Such drugs include other aminoglycosides; the antiviral acyclovir; the antifungal amphotericin B; the antibiotics bacitracin, ...
nov., an amphotericin-producing actinomycete isolated from the head of an ant (Camponotus japonicus Mayr)". International ... Streptomyces amphotericinicus produces amphotericin. List of Streptomyces species Parte, A.C. "Streptomyces". LPSN. " ...
The additional or sequential use of other nephrotoxic drugs like aminoglycosides, amphotericin B, capreomycin, colistin, ...
Systemic: amphotericin B#, hamycin‡. Squalene monooxygenase. inhibitors. Allylamines. *Topical: naftifine. *terbinafine. ...
Amphotericin B is nephrotoxic when given intravenously. As a polyene's hydrophobic chain is shortened, its sterol binding ... Baginski M, Czub J (June 2009). "Amphotericin B and its new derivatives - mode of action". Current Drug Metabolism. 10 (5): 459 ... However, at therapeutic doses, some amphotericin B may bind to animal membrane cholesterol, increasing the risk of human ...
Systemic: amphotericin B#, hamycin‡. Squalene monooxygenase. inhibitors. Allylamines. *Topical: naftifine. *terbinafine. ...
Amphotericin B is another option. Among individuals being treated in intensive care units, the mortality rate is about 30-50% ... A number of weeks of intravenous amphotericin B may be used as an alternative. In certain groups at very high risk, antifungal ... Oral or intravenous fluconazole, itraconazole, or amphotericin B may be used if these do not work. A number of topical ... treatment with amphotericin B may be necessary. Vaginal yeast infections are typically treated with topical antifungal agents. ...
Amphotericin B has been replaced by safer agents in most circumstances, but is still used, despite its side effects, for life- ... Amphotericin B, an antifungal drug, targets ergosterol. It binds physically to ergosterol within the membrane, thus creating a ... Ellis D (February 2002). "Amphotericin B: spectrum and resistance". The Journal of Antimicrobial Chemotherapy. 49 Suppl 1: 7-10 ...
Another antimicrobial drug amphotericin B is also commonly used. Liposomal amphotericin B (L-AmB) has been a drug of choice in ... Further, amphotericin B has severe adverse effects. Its acute effects includes nausea, vomiting, rigors, fever, hypertension or ... Laniado-Laborín, Rafael; Cabrales-Vargas, Maria Noemí (2009). "Amphotericin B: side effects and toxicity". Revista ...
Amphotericin B has also been used. The prognosis for chromoblastomycosis is very good for small lesions. Severe cases are ... treatment with a combination of amphotericin B and 5-flucytosine". Br. J. Dermatol. 152 (3): 560-4. doi:10.1111/j.1365- ... "Extensive chromoblastomycosis caused by Fonsecaea pedrosoi successfully treated with a combination of amphotericin B and ...
Torrado, J. J.; Espada, R.; Ballesteros, M. P.; Torrado-Santiago, S. (2008). "Amphotericin B Formulations and Drug Targeting". ... antifungal therapy through administering Amphotericin B (AMB) proved ineffective. AMB is a common and leading antibiotic ...
Treatment with amphotericin B has been reported. Cattle can be affected by protothecal enteritis and mastitis. Protothecal ...
Treatment with amphotericin B has been reported. Scientists have been researching new ways to fight protozoan infections, ... Only FDA approved for visceral leishmaniasis is amphotericin B and oral miltefosine for cutaneous and mucosal leishmaniasis ...
Amphotericin B is nephrotoxic when given intravenously. As a polyene's hydrophobic chain is shortened, its sterol binding ... Amphotericin B Candicidin Filipin - 35 carbons, binds to cholesterol (toxic) Hamycin Natamycin - 33 carbons, binds well to ... Baginski M, Czub J (June 2009). "Amphotericin B and its new derivatives - mode of action". Current Drug Metabolism. 10 (5): 459 ... However, at therapeutic doses, some amphotericin B may bind to animal membrane cholesterol, increasing the risk of human ...
Amphotericin B, nystatin, and natamycin are examples of polyene antimycotics. They are a subgroup of macrolides. Their chemical ... Khan N, Rawlings B, Caffrey P (Jan 26, 2011). "A labile point in mutant amphotericin polyketide synthases". Biotechnol. Lett. ... "Amphotericin forms an extramembranous and fungicidal sterol sponge". Nature Chemical Biology. 10 (5): 400-406. doi:10.1038/ ...
Aminoglycosides - use of them is extremely restricted due to risk of hearing loss and kidney damage; Amphotericin B - used for ...
Treatment includes amphotericin B, posaconazole, itraconazole, and fluconazole. The majority of the cases of infection are ...
Mishra proposed the use of Amphotericin B (Fungizone) to combat the disease through an article he published in Lancet in 1991. ... India portal Leishmaniasis Amphotericin B "India Medical Times". India Medical Times. 2014. Retrieved 5 November 2014. "News ... and its treatment using Amphotericin B, regarded by many as a pioneering attempt. The Government of India honoured him, in 2014 ...
... is susceptible to amphotericin B and flucytosine. Rhodotorula can also cause infections in animals. There have been ...
Amphotericin B therapy was administered but symptoms persisted. Within two months of transplant, the patient experienced a ... There is concern about amphotericin B resistance in S. candida. The anamorph was first documented, unintentionally, by ... and amphotericin B to treat the fungal infection. Subsequent identification of S. candida as the cause of disease prompted ... and exhibited high resistance to amphotericin B in vitro. In 1989, the species responsible for the disseminated infection was ...
Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific. European ... Richie DL, Ghannoum MA, Isham N, Thompson KV, Ryder NS (2012). "Nonspecific effect of Mycograb on amphotericin B MIC". ... in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for ...
Antimony resistant so amphotericin B is recommended. L. infantum[23] *Amphotericin B ...
Amphotericin B deoxycholate is the most common treatment antifungal agent used to treat Candida infections. Topical antifungal ... Micafungin, compared to amphotericin B, it is more efficient. Anidulafungin results are similar to Caspofungin and Micafungin. ... For invasive disease, treatments include amphotericin B, echinocandins, or extended-spectrum triazole antifungals. In the ...
Amphotericin B functions by binding to sterols in the cell membrane of fungi leading to change in membrane permeability ... Amphotericin B, a drug primarily used for treatment of patients with progressive and potentially life threatening fungal ... CS1 maint: discouraged parameter (link) "Amphotericin B". Drugs.com. Retrieved 21 November 2017. CS1 maint: discouraged ...
McCurdy DK, Frederic M, Elkinton JR (1968). "Renal tubular acidosis due to amphotericin B". N. Engl. J. Med. 278 (3): 124-30. ... Toxins, including ifosfamide (more commonly causing pRTA than dRTA), lithium carbonate and amphotericin B. Chronic urinary ...
Chunn CJ, Starr PR, Gilbert DN (August 1977). "Neutrophil toxicity of amphotericin B". Antimicrobial Agents and Chemotherapy. ...
Amphotericin B. *Evt. ekstra Fluconazol mod Candida. *Interferon gamma 3x ugtl.: Nedsætter hyppigheden af infektioner med 70 % ...
... is a macrolide antibiotic (CHEBI:25105) amphotericin B (CHEBI:2682) is a polyene antibiotic (CHEBI: ... amphotericin B (CHEBI:2682) has role bacterial metabolite (CHEBI:76969) amphotericin B (CHEBI:2682) is a antibiotic antifungal ... amphotericin B methyl ester (CHEBI:277842) has functional parent amphotericin B (CHEBI:2682). ... CHEBI:2682 - amphotericin B. Main. ChEBI Ontology. Automatic Xrefs. Reactions. Pathways. Models. ...
Five cases are described in which fear of the possibly hazardous effects of giving amphotericin to patients with kidney disease ... Amphotericin Pharmacophobia. Br Med J 1973; 4 doi: https://doi.org/10.1136/bmj.4.5890.460 (Published 24 November 1973) Cite ... resulted in death from progressive infection by an amphotericin-sensitive fungus (Cryptococcus neoformans in three cases, ...
AmBisome infusion contains the active ingredient amphotericin, which is a type of medicine called an antifungal. It is used to ... AmBisome (amphotericin). AmBisome infusion contains the active ingredient amphotericin, which is a type of medicine called an ... amphotericin must be given by a drip into a vein (intravenous infusion). Unfortunately amphotericin given in this way commonly ... Amphotericin may be less effective at treating infection if it is used in combination with azole-type antifungals such as ...
Fungizone infusion contains the active ingredient amphotericin, which is a type of medicine called an antifungal. It is used to ... Fungizone (amphotericin). Fungizone infusion contains the active ingredient amphotericin, which is a type of medicine called an ... Fungizone infusion is a conventional water-based form of amphotericin. Unfortunately, this form of amphotericin commonly causes ... Amphotericin may be less effective at treating infection if it is used in combination with azole-type antifungals such as ...
... type is the antifungal agent amphotericin B, which binds to a specific molecule (ergosterol) found in fungal cells. This ... Other articles where Amphotericin B is discussed: drug: Membrane lipids: … ... Polyenes, such as amphotericin B and nystatin, are macrolide antibiotics made up of alternating conjugated double bonds. The ... type is the antifungal agent amphotericin B, which binds to a specific molecule (ergosterol) found in fungal cells. This ...
Effects of Fluid and Electrolyte Management on Amphotericin B-Induced Nephrotoxicity Among Extremely Low Birth Weight Infants ...
Amphotericin B Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... You may receive amphotericin B injection in a hospital or you may use the medication at home. If you will be using amphotericin ... Before receiving amphotericin B injection,. *tell your doctor and pharmacist if you are allergic to amphotericin B, any other ... Amphotericin B injection is used to treat serious and potentially life-threatening fungal infections. Amphotericin B injection ...
I work peds onc and we use a lot of amphotericin B and liposomal ampho if the kids cant handle the regular. We treat regular ... I work peds onc and we use a lot of amphotericin B and liposomal ampho if the kids cant handle the regular. We treat regular ... I have had children develop seizures from amphotericin. Some of the other drugs you listed also change the seizure threshold. ...
Amphotericin B Liposomal Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving amphotericin B liposomal injection,. *tell your doctor and pharmacist if you are allergic to amphotericin B, ... You may receive amphotericin B liposomal injection in a hospital or you may use the medication at home. If you will be using ... Amphotericin B liposomal injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go ...
Many of the important biologic properties of amphotericin B may be ascribed to binding by certain sterols in fungal and ... Many of the important biologic properties of amphotericin B may be ascribed to binding by certain sterols in fungal and ... Bennett J.E. (1976) Review of Amphotericin B. In: Williams J.D., Geddes A.M. (eds) Parasites, Fungi, and Viruses. Chemotherapy ... Avid binding to serum proteins, probably coupled at least in part by cholesterol, makes amphotericin B equilibrate slowly with ...
Two amphotericins, amphotericin A and amphotericin B, are known, but only B is used clinically, because it is significantly ... Amphotericin A is almost identical to amphotericin B (having a C=C double bond between the 27th and 28th carbons), but has ... This is amphotericin Bs primary effect as an antifungal agent. It has been found that the amphotericin B/ergosterol ... Amphotericin B deoxycholate (ABD) is administered intravenously. As the original formulation of amphotericin, it is often ...
A list of US medications equivalent to Ambisome Liposomal Amphotericin B is available on the Drugs.com website. ... Ambisome Liposomal Amphotericin B is a medicine available in a number of countries worldwide. ... Amphotericin B. Amphotericin B liposomal (a derivative of Amphotericin B) is reported as an ingredient of Ambisome Liposomal ... Ambisome Liposomal Amphotericin B. Ambisome Liposomal Amphotericin B may be available in the countries listed below. ...
AMPHOTERICIN B (am foe TER i sin) is an antifungal medicine. It is used to treat certain kinds of fungal or yeast infections. ... Amphotericin B for infusion. What is this medicine?. AMPHOTERICIN B (am foe TER i sin) is an antifungal medicine. It is used to ... an unusual or allergic reaction to amphotericin B, other medicines, foods, dyes or preservatives ...
Red man syndrome associated with amphotericin B.. BMJ 1990; 300 doi: https://doi.org/10.1136/bmj.300.6737.1468 (Published 02 ...
Amphotericin B definition is - an antibiotic that is obtained from a soil streptomycete (Streptomyces nodosus) and is ... Comments on amphotericin B. What made you want to look up amphotericin B? Please tell us where you read or heard it (including ... Post the Definition of amphotericin B to Facebook Share the Definition of amphotericin B on Twitter ... Examples of amphotericin B in a Sentence. Recent Examples on the Web All the specimens could flout fluconazole, but four of the ...
Easy-to-read patient leaflet for Amphotericin B (Lipid Complex). Includes indications, proper use, special instructions, ... Uses of Amphotericin B:. *It is used to treat fungal infections. What do I need to tell my doctor BEFORE I take Amphotericin B? ... Amphotericin B (Lipid Complex). Generic Name: Amphotericin B (Lipid Complex) (am foe TER i sin bee LIP id KOM pleks). Brand ... How do I store and/or throw out Amphotericin B?. *If you need to store amphotericin B (lipid complex) at home, talk with your ...
... is used to treat serious, life-threatening fungal infections including leishmaniasis, and a certain ... Amphotericin B liposomal is an antifungal medication that fights infections caused by fungus. ... form of meningitis in people infected with HIV (human immunodeficiency virus). Amphotericin B... ... How is amphotericin B liposomal given?. Amphotericin B liposomal is injected into a vein through an IV. You will receive this ...
Read more about the prescription drug AMPHOTERICIN - INJECTION. ... GENERIC NAME: AMPHOTERICIN - INJECTION (AM-foe-TER-i-sin). ... Consumer information about the medication AMPHOTERICIN - INJECTION (Fungizone), includes side effects, drug interactions, ... WARNING: Amphotericin should be used only to treat serious, possibly fatal fungal infections. This medication should not be ... PRECAUTIONS: Before using amphotericin, tell your doctor or pharmacist if you are allergic to it; or if you have any other ...
Get an overview of AMPHOTERICIN B (injection, powder, lyophilized, for solution), including warnings and precautions, ... The medication in Amphotericin B can be sold under different names. Refer to the "Also Known As" section to reference different ... Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as ... Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening ...
Amphotericin B is an antifungal agent that is used both topically and systemically for various fungal infections, especially ... Amphotericin B (Fungizone). Amphotericin B is an antifungal agent that is used both topically and systemically for various ...
AMBISOME (amphotericin b) injection, powder, lyophilized, for solution NDC Code(s): 0469-3051-30 ... amphotec (Amphotericin B) injection, lipid complex NDC Code(s): 64116-021-01, 64116-025-01 ... AMPHOTERICIN B injection, powder, lyophilized, for solution NDC Code(s): 39822-1055-5 ... ABELCET (amphotericin b, dimyristoylphosphatidylcholine, dl- and dimyristoylphosphatidylglycerol, dl-) injection NDC Code(s): ...
Drug classes of Amphotericin. *Antifungal Therapeutic actions of Amphotericin. As with other polyene antifungals, amphotericin ... Indications of Amphotericin. Oral preparations of amphotericin B are rarely used. *The main use is in systemic fungal ... Contraindications/cautions of Amphotericin. Hypersensitivity to amphotericin or any component of the forumulation. ... Adverse effects of Amphotericin. * Side-effects can be severe; nephrotoxicity (kidney damage) is a major issue. Other side- ...
WebMD provides information about interactions between Depoject-80 Injection and corticosteroids-corticotropin-acth-amphotericin ... 1.Amphotericin B US prescribing information. X-Gen Pharmaceuticals September, 2005.. *2.Chung DK, Koenig MG. Reversible cardiac ... Amphotericin B/Corticosteroids; Corticotropin (ACTH) Interactions. This information is generalized and not intended as specific ... enlargement during treatment with amphotericin B and hydrocortisone. Report of three cases. Am Rev Respir Dis 1971 Jun;103(6): ...
Amphotericin B) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related ... Amphotericin B. AmBisome. Amphotericin B. Total number of patients receiving at least one dose of study drug. 48. 47. 295. 297 ... Amphotericin B is a macrocyclic, polyene, antifungal antibiotic produced from a strain of Streptomyces nodosus. Amphotericin B ... What are the possible side effects of amphotericin B liposomal (AmBisome)?. Some people receiving a amphotericin B liposomal ...
... is an antifungal drug. Topically, it is used to treat skin yeast infections. Intravenously, it is used to treat ... Amphotericin B. Drug Information. Amphotericin B is an antifungal drug. Topically, it is used to treat skin yeast infections. ... Amphotericin B has been reported to increase urinary excretion of magnesium. It remains unclear whether it is important for ...
Amphotericin B/Fungizone. Amphotericin B/Fungizone. *for severe systemic fungal infections;. *dose: 0.25mg/kg IV over 6hrs ... Amphotericin B-loaded bone cement to treat osteomyelitis caused by Candida albicans ... Amphotericin B Delivery From Bone Cement Increases With Porosity but Strength Decreases ...
This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.. ...
Amphotericin B solution for your research needs. Find product specific information including CAS, MSDS, protocols and ... This product is supplied as 250 μg/mL Amphotericin B in deionized water. It is a solution containing Amphotericin B, and the ... Amphotericin B solution 250 μg/mL in deionized water, sterile-filtered, BioReagent, suitable for cell culture ... Amphotericin B solution has been used-. • as an intraperitoneal injection for the treatment of Aspergillus fumigatus infection ...
In contrast, amphotericin B at the same concentrations had little or no effect on spontaneous natural killer cell activity in ... Effect of amphotericin B on natural killer cell activity in vitro.. Hauser WE Jr, Remington JS. ... Incubation of murine peritoneal and spleen natural killer cells with amphotericin B at concentrations of 2.5, 5 and 10 mg/l in ... These in-vitro data suggest amphotericin B may have adverse effects on natural killer cell function in vivo. ...
Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability.. Cheng JT, Witty RT, Robinson RR, Yarger WE. ... Two groups of rats received amphotericin-B (Amp). One group (AA) received a single acute dose of 1 mg/kg i.v. The second (CA) ...
  • Amphotericin B deoxycholate (ABD) is administered intravenously. (wikipedia.org)
  • They are more expensive than amphotericin B deoxycholate. (wikipedia.org)
  • Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis ) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. (rxlist.com)
  • It is a solution containing Amphotericin B, and the following components aimed to improve its solubility: sodium deoxycholate, sodium chloride and sodium phosphate. (sigmaaldrich.com)
  • We report nanomicelles of amphotericin B (AmB) using various molar ratios of AmB and sodium deoxycholate sulfate (SDCS) for inhalation with improved stability, solubility, bioactivity, and safety. (springer.com)
  • Treatment with amphotericin B deoxycholate (AB) is associated with dose-related nephrotoxicity. (ajtmh.org)
  • Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate. (ajtmh.org)
  • Intrathecal amphotericin B deoxycholate (AmB-d) can be prescribed as an adjunct to systemic therapy for severe or recalcitrant cases coccidioidal meningitis. (bioportfolio.com)
  • This short course treatment strategy is now being tested against amphotericin B deoxycholate in a clinical end point trial. (eatg.org)
  • Nephrotoxicity associated with deoxycholate amphotericin B (D-AMB) is well documented in adults and has been reported to occur less frequently with L-AMB. (empr.com)
  • Dr. Liao and colleagues performed a retrospective analysis to evaluate nephrotoxicity associated with deoxycholate amphotericin B (D-AMB) and L-AMB use in neonates. (empr.com)
  • For the treatment of CNS infections, including meningitis, in patients refractory to or intolerant of amphotericin B deoxycholate. (pdr.net)
  • For the treatment of candidemia and invasive candidiasis (non-CNS) in patients refractory to or intolerant of amphotericin B deoxycholate. (pdr.net)
  • Despite their high toxicity, antimonials and amphotericin B deoxycholate are commonly used for treating visceral leishmaniasis (VL). (scielo.br)
  • This study aimed to evaluate efficacy and safety of amphotericin B deoxycholate vs. that of N-methylglucamine antimoniate in treating pediatric VL in Brazil. (scielo.br)
  • Treatment naïve children and adolescents with VL without signs of severe illness were treated with N-methylglucamine antimoniate (20mg/kg/day for 20 days) or amphotericin B deoxycholate (1 mg/kg/day for 14 days). (scielo.br)
  • N-methylglucamine antimoniate and amphotericin B deoxycholate have similar efficacy and adverse events rate in pediatric patients with VL. (scielo.br)
  • Therefore, the aim of this study was to estimate the efficacy and safety of amphotericin B deoxycholate (ABD) through a randomized and controlled clinical trial compared to meglumine antimoniate (MA) in children with VL treated in reference centers of Palmas (Tocantins' State Capital) and Araguaína, the two most populated cities in the state of Tocantins, Brazil. (scielo.br)
  • Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. (biomedsearch.com)
  • AmBisome infusion contains the active ingredient amphotericin, which is a type of medicine called an antifungal. (netdoctor.co.uk)
  • Ambisome is usually only used in people who cannot be given conventional amphotericin, for example because they have kidney problems). (netdoctor.co.uk)
  • AmBisome infusion is a lipid-based formulation of amphotericin that is less likely to cause side effects than conventional amphotericin infusion (Fungizone). (netdoctor.co.uk)
  • People who can't be given Fungizone due to problems with its side effects, particularly its kidney side effects, may be given a liposomal form of amphotericin, such as Abelcet or AmBisome, as higher doses of these can be given with fewer side effects. (netdoctor.co.uk)
  • AmBisome (LAMB) is a liposomal formulation of amphotericin B for injection and consists of a mixture of phosphatidylcholine, cholesterol and distearoyl phosphatidylglycerol that in aqueous media spontaneously arrange into unilamellar vesicles that contain amphotericin B. It was developed by NeXstar Pharmaceuticals (acquired by Gilead Sciences in 1999). (wikipedia.org)
  • Ambisome Liposomal Amphotericin B may be available in the countries listed below. (drugs.com)
  • The side-effects are much milder when amphotericin B is delivered in liposomes ( AmBisome ). (doctorslounge.com)
  • AmBisome consists of these unilamellar bilayer liposomes with amphotericin B intercalated within the membrane. (rxlist.com)
  • Due to the nature and quantity of amphophilic substances used, and the lipophilic moiety in the amphotericin B molecule, the drug is an integral part of the overall structure of the AmBisome liposomes. (rxlist.com)
  • What are the possible side effects of amphotericin B liposomal (AmBisome)? (rxlist.com)
  • AmBisome contains liposomal amphotericin B. Its WHO recommended use is for the treatment of systemic mycotic infections and of visceral leishmaniasis in HIV/AIDS infected patients. (who.int)
  • You should not receive this medicine if you are allergic to any formulation of amphotericin B (Abelcet, AmBisome, Amphocin, Amphotec, or Fungizone). (wellspan.org)
  • Thank you for raising your concerns regarding access to AmBisome® (liposomal amphotericin B). (gilead.com)
  • Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case. (bioportfolio.com)
  • The efficacy of AmBisome, a liposomal formulation of amphotericin B, was compared with that of Fungizone (amphotericin B desoxycholate), in a rat model of unilateral, pulmonary aspergillosis. (biomedsearch.com)
  • In order to improve the tolerability of amphotericin and reduce toxicity, several lipid formulations have been developed. (wikipedia.org)
  • Despite its toxicity amphotericin B is the drug of choice for treatment of most fungal infections. (annals.org)
  • Amphotericin B formulations: a comparative review of efficacy and toxicity. (springer.com)
  • Amphotericin B: side effects and toxicity. (springer.com)
  • Combined intrastromal injection of amphotericin B and topical fluconazole can provide a good modality in the treatment of resistant cases of fungal keratitis, exhibiting highly potent antifungal effects, shorter recovery period, and reduced corneal toxicity. (dovepress.com)
  • Furthermore, amphotericin B was not given under optimal circumstances, with premedication to reduce infusion-related toxicity , slow infusion, and with fluid, potassium and magnesium supplements to prevent nephrotoxicity. (cochrane.org)
  • The major harms were hepatic impairment and gastrointestinal adverse effects with fluconazole and infusion-related toxicity , renal impairment and gastrointestinal adverse effects with amphotericin B. For the 2011 and 2014 updates no additional trials were identified for inclusion. (cochrane.org)
  • This is a model of amphotericin, the most relied-upon drug for treating fungal infections, despite its toxicity. (phys.org)
  • Amphotericin B induced ocular toxicity in cryptococcal meningitis. (bmj.com)
  • The therapeutic use of polyene antibiotic amphotericin B is known to produce a number of toxic side effects such as fever, chills, nausea, vomiting, headache and renal dysfunction with associated anoxia, hypoxalamine, nephrotoxicity including myocardial toxicity. (abebooks.co.uk)
  • Amphotericin B associated cellular toxicity in part has been shown to be due to lipid peroxide damage in many experimental studies. (abebooks.co.uk)
  • Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. (nih.gov)
  • Amphotericin B nephrotoxicity. (ajtmh.org)
  • Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. (ajtmh.org)
  • Effect of salt supplementation on amphotericin B nephrotoxicity. (ajtmh.org)
  • Liposomal formulations of amphotericin were developed to address concerns of nephrotoxicity based mostly on evidence in adult population. (empr.com)
  • However, the incidence of nephrotoxicity associated with amphotericin B use in neonates ranges from 0-60% and is poorly defined among this population. (empr.com)
  • Although the treatment of choice has traditionally been amphotericin B, some infants experience nephrotoxicity during treatment, which compromises their ability to complete the treatment. (bmj.com)
  • Some infants have underlying renal disease or are given other nephrotoxic drugs that can potentiate the nephrotoxicity of amphotericin B. (bmj.com)
  • 1 An effective drug that does not have the dose limiting nephrotoxicity of amphotericin B could improve the care of neonates with invasive fungal infections. (bmj.com)
  • Can mannitol reduce amphotericin b nephrotoxicity? (biomedsearch.com)
  • be treated with the antibiotic amphotericin B. (britannica.com)
  • Amphotericin B is a macrocyclic, polyene, antifungal antibiotic produced from a strain of Streptomyces nodosus . (rxlist.com)
  • Amphotericin B is a polyene antifungal antibiotic from Streptomyce sp. (sigmaaldrich.com)
  • Amphotericin B is a polyene antifungal antibiotic that is clinically used to treat systemic fungal infections. (sigmaaldrich.com)
  • This antibiotic solution is formulated as follows: Penicillin 10,000 Units/mL, Streptomycin 10 mg/mL, Amphotericin B 25 µg/mL. (atcc.org)
  • are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses. (drugbank.ca)
  • Thus, they were treated with a single intrastromal injection of amphotericin B in addition to topical fluconazole as combined antifungal therapy, representing group A. Twenty-seven cases were treated with topical amphotericin B as antifungal monotherapy, representing group B. Topical atropine 1% and different antibiotic eye drops were added to the antifungal agents in both groups. (dovepress.com)
  • Also amphotericin B. One of two antifungal antibiotic s, the other designated amphotericin A (not used clinically), derived from a strain of Streptomyces nodosus and effective against a wide range of fungi and against some species of Leishmania. (lymphedemapeople.com)
  • Etest assays with RPMI and antibiotic medium 3 (AM3) agar were compared to the NCCLS M27-A broth macrodilution method using AM3 for amphotericin B resistance testing with 49 clinical isolates of C. lusitaniae . (asm.org)
  • PubMed ID 20147716) used the antifungal and cell culture antibiotic, amphotericin B, to treat visceral leishmaniasis in India. (scbt.com)
  • Amphotericin B is an antifungal and useful cell culture antibiotic. (scbt.com)
  • Fungizone infusion is a conventional water-based form of amphotericin. (netdoctor.co.uk)
  • You may receive amphotericin B injection in a hospital or you may use the medication at home. (medlineplus.gov)
  • In a 27-center study, 231 patients with hematogenous or organinfection caused by Candida species, 50% of whom had cancer,were randomly assigned to receive amphotericin B lipid complex,5 mg/kg/day, or standard amphotericin B, 1 mg/kg/day, for a medianduration of 14 days. (cancernetwork.com)
  • What should I discuss with my health care provider before I receive amphotericin B? (wellspan.org)
  • Arm I: Patients receive amphotericin B-liposomal formulation IV over 1 hour on day 3 of febrile neutropenia. (bioportfolio.com)
  • The efficacy and safety profile of liposomal amphotericin B is well established based on the extensive clinical experience in the treatment fungal infections. (who.int)
  • A prospective, randomized, multicen-ter trial was set up to comparethe efficacy and safety of the two amphotericin B products astreatment for invasive candi-diasis, Dr. Anaissie said. (cancernetwork.com)
  • Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. (annals.org)
  • However, Amphotericin B's high molecular weight compared to other antifungal drugs, such as miconazole and clotrimazole, and poor water solubility hampers its efficacy at the physiological conditions of the oropharyngeal cavity (saliva pH, limited volume for dissolution) and thereby limits its clinical use in oropharyngeal candidiasis. (mdpi.com)
  • To evaluate the efficacy of combination therapy of a single intrastromal injection of amphotericin B and topical fluconazole in resistant cases of fungal keratitis, and also topical amphotericin B as monotherapy in terms of the duration of the recovery period and toxic drug effects. (dovepress.com)
  • Compare the efficacy and side effects of amphotericin B-liposomal formulation initiated 72-84 hours vs 144-156 hours after onset of a febrile episode in cancer patients with granulocytopenia and persistent unexplained fever refractory to antibacterials. (bioportfolio.com)
  • The purpose of this trial is to evaluate the efficacy of single dose amphotericin B in the treatment of Visceral Leishmaniasis (VL) in India. (bioportfolio.com)
  • SAN FRANCISCO, CA -The increased use of liposomal amphotericin B (L-AMB) in neonates has occurred without evidence of increased efficacy or safety, presented Siyun Liao, PharmD, from the University of Illinois, Chicago, IL, at IDWeek 2013. (empr.com)
  • This study describes the safety and efficacy of amphotericin B lipid complex (ABLC) in 11 neonates with systemic Candida infections. (bmj.com)
  • Although three lipid based amphotericin B products are available in many countries, to date there are few data on their safety and efficacy in neonates. (bmj.com)
  • similar spectrum of activity and efficacy as conventional amphotericin B. (pdr.net)
  • METHODS: A phase II randomized, parallel arm, open-labelled trial is being conducted to assess the efficacy of each of the three regimens: liposomal amphotericin B with SSG, Liposomal amphotericin B with miltefosine and miltefosine alone. (uva.nl)
  • To determine the concentrations of amphotericin B achieved in the epithelial lining fluid, and serum with the administration of a four days of lipid complex of amphotericin B (Abelcet ®) (QD) via aerosolized nebulization in lung transplant recipients. (clinicaltrials.gov)
  • The purpose of this study is to determine the optimal delivery system for the nebulization of the lipid complex amphotericin B (Abelcet ®) in lung transplant recipients who are positive for invasive aspergillosis (IA) in their lungs. (clinicaltrials.gov)
  • Read user comments about the side effects, benefits, and effectiveness of amphotericin B cholesteryl sulfate complex intravenous. (webmd.com)
  • Sophie Cousins, National Geographic , "Drug-resistant superbug thriving in hospitals hit hard by COVID-19," 23 Oct. 2020 Doctors immediately started her on a large cocktail of drugs including amphotericin B and miltefosine. (merriam-webster.com)
  • This is not a list of all drugs or health problems that interact with amphotericin B (lipid complex). (drugs.com)
  • You must check to make sure that it is safe for you to take amphotericin B (lipid complex) with all of your drugs and health problems. (drugs.com)
  • What other drugs will affect amphotericin B? (wellspan.org)
  • Other drugs may interact with amphotericin B, including prescription and over-the-counter medicines, vitamins, and herbal products. (wellspan.org)
  • Search [email protected] to access more information on amphotericin B, including additional drug labels and any generic equivalents. (nih.gov)
  • RATIONALE: Drugs like liposomal amphotericin B may be able to relieve fungal infection which can be a side effect of chemotherapy. (bioportfolio.com)
  • India has 27,142 active cases of Mucormycosis, also known as black fungus, and if the number rises, the country is prepared to increase the availability of Amphotericin B and other drugs used in the treatment of the disease, Union Minister Mansukh Mandaviya said on Friday. (moneycontrol.com)
  • Even in the future, if cases of Black fungus increases , India is prepared to have more than sufficient availability of Amphotericin B and other drugs which are required to treat patients of Mucormycosis," Mandaviya said in a tweet. (moneycontrol.com)
  • India is leaving no stone unturned to boost the availability of Amphotericin B drugs in the country," Mandaviya noted. (moneycontrol.com)
  • As lipid complex amphotericin B: In patients not responding to conventional amphotericin B or to other antifungal drugs: Test dose 1 mg infused over 15 minutes, then 5 mg/kg once daily via infusion at a rate of 2.5mg/kg/hour. (mims.com)
  • Liposomal amphotericin B (LAMB), alone or in combination with other drugs, has been extensively studied as VL treatment, but data on routine field use are limited, and several challenges to patients' access to this life-saving drug remain. (msfaccess.org)
  • Lipid-based formulations of amphotericin B are no more effective than conventional formulations, although there is some evidence that lipid-based formulations may be better tolerated by patients and may have fewer adverse effects. (wikipedia.org)
  • Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemoth. (springer.com)
  • Recent Examples on the Web All the specimens could flout fluconazole, but four of the C. auris isolates were also resistant to amphotericin B , a second-line antifungal drug. (merriam-webster.com)
  • Since intravenous amphotericin B is the only antifungal agent for which an effect on mortality has been shown, and since it is considerably cheaper than fluconazole, it should be the preferred agent. (cochrane.org)
  • Randomised clinical trials comparing fluconazole with amphotericin B. (cochrane.org)
  • Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. (cochrane.org)
  • To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis in pat. (bioportfolio.com)
  • Short course, high dose liposomal amphotericin B (L-AmB) in combination with high dose fluconazole effectively treats HIV -associated cryptococcal meningitis, according to a study recently published in Clinical Infectious Diseases . (eatg.org)
  • More than 3 days of amphotericin B, fluconazole, or ketoconazole. (nih.gov)
  • Clinical practice guidelines suggest a lipid formulation amphotericin B as an alternative to an echinocandin or fluconazole if there is resistance or intolerance. (pdr.net)
  • Amphotec is a complex of amphotericin and sodium cholesteryl sulfate in a 1:1 ratio. (wikipedia.org)
  • Amphotericin B liposomal injection is used to treat fungal infections such as cryptococcal meningitis (a fungal infection of the lining of the spinal cord and brain) and visceral leishmaniasis (a parasitic disease that usually affects spleen, liver, and bone marrow) in certain people. (medlineplus.gov)
  • Short Course High-dose Liposomal Amphotericin B for HIV-associated Cryptococcal Meningitis: A phase-II Randomized Controlled Trial. (bioportfolio.com)
  • We report a case of acute visual loss after a test dose (1 mg) of intravenous amphotericin B administered to a patient with systemic lupus erythematosus and with cryptococcal meningitis. (bmj.com)
  • Our findings suggest that amphotericin B should be withheld in the treatment of cryptococcal meningitis if disease of the optic nerve is strongly suspected. (bmj.com)
  • These in-vitro data suggest amphotericin B may have adverse effects on natural killer cell function in vivo. (nih.gov)
  • The most frequent adverse reactions (very common ( 1/10)) observed during treatment with liposomal amphotericin B are hypokalaemia, nausea, vomiting, fever and chills/rigors, as infusion-related reactions and pyrexia. (who.int)
  • The most serious adverse reactions of amphotericin B are convulsion cardiac arrest, renal failure, anaphylaxis and rhabdomyolysis. (who.int)
  • Adverse effect of amphotericin B administration on renal hemodynamics in the rat. (aspetjournals.org)
  • Amphotericin B is an antifungal agent that is used both topically and systemically for various fungal infections, especially invasive infections caused by Candida . (fsu.edu)
  • Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. (drugbank.ca)
  • While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. (drugbank.ca)
  • Amphotericin B possesses high activity against Candida spp. (mdpi.com)
  • Both intrinsic and acquired resistance to amphotericin B have been documented for Candida lusitaniae . (asm.org)
  • Comparison of amphotericin B and nystatin pessaries in Candida infection of the vagina. (bmj.com)
  • This means it can be given at higher doses than conventional amphotericin. (netdoctor.co.uk)
  • It is reserved for treating severe invasive fungal infections in people who cannot be given conventional amphotericin, for example because they have kidney problems. (netdoctor.co.uk)
  • It is also used to treat certain fungal infections in people who cannot receive conventional amphotericin B therapy. (medlineplus.gov)
  • As the original formulation of amphotericin, it is often referred to as "conventional" amphotericin. (wikipedia.org)
  • Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. (springer.com)
  • IV Severe systemic fungal infections As conventional amphotericin B: Test dose 1 mg infused over 20-30 minutes. (mims.com)
  • As conventional amphotericin B: Test dose 1 mg infused over 20-30 minutes. (mims.com)
  • Others fail to respond to conventional doses of amphotericin B and may not tolerate increased doses. (bmj.com)
  • Amphotericin B lipid complex (ABLC) is licensed in the United States for the treatment of invasive fungal infections in adults and children who are refractory to or intolerant of conventional amphotericin B. ABLC is less nephrotoxic at higher concentrations than amphotericin B in animal models and humans. (bmj.com)
  • However, recently novel nanoparticulate drug delivery systems such as AmbiOnp, nanosuspensions, lipid-based drug delivery systems including cochleates, self-emulsifying drug delivery systems, solid lipid nanoparticles and polymeric nanoparticles-such as Amphotericin B in pegylated polylactide coglycolide copolymer nanoparticles-have demonstrated potential for oral formulation of amphotericin B. Amphotericin B is well known for its severe and potentially lethal side effects. (wikipedia.org)
  • This product is contraindicated in those patients who have shown hypersensitivity to amphotericin B or any other component in the formulation unless, in the opinion of the physician, the condition requiring treatment is life-threatening and amenable only to amphotericin B therapy. (healthgrades.com)
  • Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (Sina Ampholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis. (bioportfolio.com)
  • Clinical practice guidelines suggest a lipid formulation amphotericin B as a preferred treatment. (pdr.net)
  • Polyenes, such as amphotericin B and nystatin, are macrolide antibiotics made up of alternating conjugated double bonds. (britannica.com)
  • In two large three-armed trials, results for amphotericin B were combined with results for nystatin in a 'polyene' group. (cochrane.org)
  • You may experience a reaction while you receive a dose of amphotericin B injection. (medlineplus.gov)
  • Since amphotericin B liposomal is usually given while you are in the hospital, you are not likely to miss a dose. (rexhealth.com)
  • Therapy with intravenous amphotericin B for sporotrichosis has ranged up to nine months with a total dose up to 2.5 g. (wikidoc.org)
  • Aspergillosis has been treated with amphotericin B intravenously for a period up to 11 months with a total dose up to 3.6 g. (wikidoc.org)
  • Subject's visit for teaching and administration of the first dose of aerosolized liposomal Amphotericin will be performed at the specified intervals before the scheduled bronchoscopy. (clinicaltrials.gov)
  • Subject will receive first dose of the aerosolized liposomal amphotericin under direct supervision of physician and study coordinator. (clinicaltrials.gov)
  • Subject's spirometry will be performed before (standard of care) and after the administration (research related) of first dose aerosolized liposomal amphotericin. (clinicaltrials.gov)
  • The study is a randomized, open-label safety study comparing the use of anidulafungin (200 mg i.v. as initial dose and 100 mg/d i.v. in subsequent doses) vs liposomal amphotericin B (3 mg/kg/d i.v.) in hepatic transplant recipients who have high risk of fungal infection. (clinicaltrials.gov)
  • Patients received either low-dose (1 mg/kg) or high-dose (4 mg/kg) liposomal amphotericin B for a median of 20 and 19 days, and a total of 1,260 mg and 4,020 mg of drug, respectively. (cancernetwork.com)
  • The purpose of this trial is to see which dose of liposomal amphotericin B is the safest when used as a preventer against invasive fungal infection in patients with acute leukaemia who are. (bioportfolio.com)
  • As liposomal amphotericin B: Test dose 1 mg infused over 10 minutes, then 3 mg/kg once daily given via infusion over 30-60 minutes. (mims.com)
  • Empiric treatment of presumed fungal infection in febrile neutropenic patients As liposomal amphotericin B: Test dose 1 mg infused over 10 minutes, then 3 mg/kg once daily given via infusion over 30-60 minutes. (mims.com)
  • Visceral leishmaniasis As liposomal amphotericin B: A total dose of 21-30 mg/kg via infusion given over for 10-21 days. (mims.com)
  • B) In this study, mice were infected with a sublethal dose of 8.7 × 10 4 conidia/mouse and treated with lower doses of liposomal amphotericin B at 10 or 20 mg/kg, caspofungin at 20 mg/kg, or combined therapy. (asm.org)
  • Talk to your doctor about the risks of receiving amphotericin B injection. (medlineplus.gov)
  • Do not receive it if you had an allergic reaction to amphotericin B. (limamemorial.org)
  • Five cases are described in which fear of the possibly hazardous effects of giving amphotericin to patients with kidney disease resulted in death from progressive infection by an amphotericin-sensitive fungus (Cryptococcus neoformans in three cases, Blastomyces dermatitidis in one case, and Histoplasma capsulatum in one case). (bmj.com)
  • If you still have symptoms of infection after you finish amphotericin B injection, tell your doctor. (medlineplus.gov)
  • This is because amphotericin B resistance requires sacrifices on the part of the pathogen that make it susceptible to the host environment, and too weak to cause infection. (wikipedia.org)
  • Amphotericin B liposomal is not for treating a minor fungal infection such as a yeast infection of the mouth, esophagus, or vagina. (rexhealth.com)
  • Amphotericin B liposomal may need to be given for up several weeks or months, depending on the infection being treated. (rexhealth.com)
  • it has to be withdrawn occasionally from patients to determine whether their fever is due to amphotericin B or an actual infection. (doctorslounge.com)
  • Incubation of murine peritoneal and spleen natural killer cells with amphotericin B at concentrations of 2.5, 5 and 10 mg/l in vitro, resulted in depression of their tumoricidal activity which had been augmented in vivo by infection with Toxoplasma gondii. (nih.gov)
  • Amphotericin B will not treat a viral infection such as the common cold or flu. (wellspan.org)
  • Since patient tolerance varies greatly, the dosage of amphotericin B must be individualized and adjusted according to the patient's clinical status (e.g., site and severity of infection, etiologic agent, cardio-renal function, etc. (wikidoc.org)
  • J Investig Allergol Clin Immunol 2006;16(3):188-93) said their study indicated that long-term topical treatment with lysine acetylsalicylate and amphotericin B may be clinically effective in the treatment of patients with nasal polyposis associated with fungal infection. (enttoday.org)
  • One of the main uses of amphotericin B is treating a wide range of systemic fungal infections. (wikipedia.org)
  • Amphotericin B has been the drug of choice for most of the systemic fungal infections for 15 years. (annals.org)
  • Lipid complex amphotericin B: Dilute with dextrose 5% to a concentration of 1 mg/mL. (mims.com)
  • In contrast, amphotericin B at the same concentrations had little or no effect on spontaneous natural killer cell activity in vitro. (nih.gov)
  • An initial intravenous infusion of 1 to 5 mg of amphotericin B per day, gradually increased to 0.4 to 0.6 mg/kg daily, produces peak plasma concentrations ranging from approximately 0.5 to 2 mcg/mL. (nih.gov)
  • The next three pairs of plates contain increasing and equal concentrations of amphotericin B (top row) and itraconazole (bottom row). (aspergillus.org.uk)
  • in animal models, liposomal amphotericin B achieves higher central nervous system concentrations than other lipid formulations. (pdr.net)
  • RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or perip. (bioportfolio.com)
  • Caspofungin and amphotericin B inhibited 93% and 89% of isolates at ≤1 μg/ml, respectively, with caspofungin demonstrating an MEC 90 of 0.12 μg/ml. (asm.org)
  • at ≤1 μg/ml compared to 83% for itraconazole and 91% for amphotericin B. Amphotericin B inhibited only 38% of Aspergillus terreus isolates at ≤1 μg/ml, whereas the three new triazoles and caspofungin inhibited all A. terreus at ≤0.5 μg/ml. (asm.org)
  • We now report final 2-year results, including the in vitro activity of caspofungin, the new triazoles, amphotericin B, and itraconazole against over 400 recent clinical isolates of filamentous fungi collected from January 2000 through December of 2001. (asm.org)
  • Caspofungin was given i.p. at 20 mg/kg alone and in combination with liposomal amphotericin B. Liposomal amphotericin B was given i.v. at 30 mg/kg alone and in combination with caspofungin. (asm.org)
  • Amphotericin B was isolated from Streptomyces nodosus in 1955 and came into medical use in 1958. (wikipedia.org)
  • Amphotericin B from Streptomyces sp. (sigmaaldrich.com)
  • For more than 50 years, amphotericin B (AmB), an amphipathic polyene macrolide ( Fig. 1A ) derived from Streptomyces nodosus ( 6 ), has remained a powerful but highly toxic first line of defense against clinically severe invasive fungal infections ( 7 ) with minimal development of microbial resistance ( 8 ). (sciencemag.org)
  • While parenteral amphotericin B is an effective therapy for serious fungal infections, it frequently causes acute renal failure (ARF). (nih.gov)
  • Based on assessmentof renal function, amphotericin B lipid complex was less nephrotoxicthan standard amphotericin B. (cancernetwork.com)
  • The effect of administration of amphotericin B (AMPHO) on renal hemodynamics was studied in the rat. (aspetjournals.org)
  • Amphotericin B lipid complex, from The Liposome Company, Princeton,NJ, is a novel amphotericin B preparation complex with two lipidsin a 1:1 drug-to-lipid ratio. (cancernetwork.com)
  • Amphotericin B is used for life-threatening protozoan infections such as visceral leishmaniasis and primary amoebic meningoencephalitis. (wikipedia.org)
  • Fungisome is a generic liposomal complex of amphotericin B marketed by Lifecare Innovations of India. (wikipedia.org)
  • If you have an allergy to amphotericin or any other part of amphotericin B (lipid complex). (drugs.com)
  • Tell all of your health care providers that you take amphotericin B (lipid complex). (drugs.com)
  • You will need to talk about the benefits and risks of using amphotericin B (lipid complex) while you are pregnant. (drugs.com)
  • Use amphotericin B (lipid complex) as ordered by your doctor. (drugs.com)
  • If you need to store amphotericin B (lipid complex) at home, talk with your doctor, nurse, or pharmacist about how to store it. (drugs.com)
  • Amphotericin B liposomal complex is an antifungal and an antiprotozoal medicine. (mayoclinic.org)
  • SAN FRANCISCO-Amphotericin B lipid complex may be the treatment of choice for patients with hematogenous or invasive candidiasis, Elias J. Anaissie, MD, said at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). (cancernetwork.com)
  • SAN FRANCISCO-Amphotericin B lipid complex may be the treatmentof choice for patients with hematogenous or invasive candidiasis,Elias J. Anaissie, MD, said at the 35th Interscience Conferenceon Antimicrobial Agents and Chemotherapy (ICAAC). (cancernetwork.com)
  • In the first large randomized comparative trial of a lipid amphotericinB product vs standard amphotericin B for the treatment of candidiasis,amphotericin B lipid complex was as effective as standard ampho-tericinB, with the advantage of being less nephrotoxic, said Dr. Anaissie,associate professor of medicine, Infectious Diseases Section,University of Texas M.D. Anderson Cancer Center. (cancernetwork.com)
  • Mycologic eradication rates were also similar: 88% for patientsreceiving amphotericin B lipid complex, and 87% for patients receivingstandard ampho-tericin B. (cancernetwork.com)
  • At 3-month follow-up, Dr Anaissie said, there were no significantdifferen-ces in relapse or survival, with 60% of those on amphotericinB lipid complex remaining alive, compared with 51% of patientsreceiving standard amphotericin B. Median survival was 134 daysfor amphotericin B lipid complex patients vs 61 days for patientswho received standard amphotericin B, a positive trend in favorof amphotericin B lipid complex therapy, but not statisticallysignificant. (cancernetwork.com)
  • Using Kaplan-Meier analysis, Dr. Anaissie said, the median numberof days to doubling of the serum creatinine level was 19 daysfor patients in the standard amphotericin B group, and 82 daysfor patients receiving amphotericin B lipid complex. (cancernetwork.com)
  • The complex formed with albumin in the presence of both amphotericin and curcumin is water soluble, and it retains antifungal activity. (dovepress.com)
  • Interestingly, it was found that the presence of curcumin in the complex significantly delayed the red cell lysis by amphotericin B, indicating the possibility of moderating the toxic side effects of the drug using curcumin. (dovepress.com)
  • Clinical practice guidelines suggest amphotericin B lipid complex as salvage therapy. (pdr.net)
  • Although specific neonatal recommendations are not available, clinical practice guidelines suggest amphotericin B lipid complex as salvage therapy. (pdr.net)
  • Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. (healthgrades.com)
  • 2.Chung DK, Koenig MG. Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone. (webmd.com)
  • Amphotericin B has, until recently, been the mainstayof treatment for invasive fungal infections because of its broadspectrum of activity. (cancernetwork.com)
  • It is, therefore, imperative that diabetic control be restored in order for treatment with Amphotericin B for Injection to be successful. (wikidoc.org)
  • Comparison between placebo gel treatment to topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis of Leishmania species major and tropica. (clinicaltrials.gov)
  • NEW ORLEANS High doses of liposomal amphotericin B are no more effective than low doses in the treatment of invasive aspergillosis in neutropenic patients, European researchers reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy. (cancernetwork.com)
  • Amphotericin B is used for the treatment of Mucormycosis. (moneycontrol.com)
  • Amphotericin B remains the drug of choice for many critical fungal infections, and the detection of resistance is essential to monitor treatment effectively. (asm.org)
  • Her visual acuity was normal prior to the injection of amphotericin B. The meningitis subsequently responded to miconazole and flucytosine treatment. (bmj.com)
  • Trending serial CSF samples to guide treatment of refractory coccidioidal meningitis with intrathecal liposomal amphotericin. (bioportfolio.com)
  • After publication of their first data in Mayo Clinic Proceedings (1999;74:877-84), the team demonstrated in follow-up studies that intranasal antifungal treatment (specifically with amphotericin B) improved the objective computed tomography (CT) findings such as inflammatory mucosal thickening, nasal endoscopy stages, and CRS symptoms. (enttoday.org)
  • Others point to studies by two separate European groups that found that amphotericin B was ineffective in CRS treatment. (enttoday.org)
  • Long-term survivors of mice bearing a transplanted leukemia have been obtained following treatment with a combination of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea. (aacrjournals.org)
  • Hence there is a need to explore alternative treatment protocols such as miltefosine alone or in combinations including miltefosine, sodium stibogluconate (SSG) or liposomal amphotericin B. The aim of this trial is to identify regimen(s) which are sufficiently promising for future trials in East Africa. (uva.nl)
  • Thrombocytopenia has been noted in patients receiving amphotericin B (2). (annals.org)
  • In view of the toxic side effects exerted by Amphotericin B and physiological roles assigned to NO, present study examined the in vivo effect of selected doses of Amphotericin B on NO pathway parameters in animal Albino rat model. (abebooks.co.uk)
  • Amphotericin B is an antifungal medication used for serious fungal infections and leishmaniasis. (wikipedia.org)
  • Amphotericin B liposomal is used to treat serious, life-threatening fungal infections including leishmaniasis, and a certain form of meningitis in people infected with HIV (human immunodeficiency virus). (rexhealth.com)
  • In addition to Amphotericin B's antifungal activity it has been used against leishmaniasis caused by protozoan parasites of the Leishmania genus . (scbt.com)
  • Effect of amphotericin B on natural killer cell activity in vitro. (nih.gov)
  • Amphotericin B shows a high order of in vitro activity against many species of fungi. (drugbank.ca)
  • The panel included nine isolates with known or presumed resistance to amphotericin B on the basis of in vivo and/or in vitro data. (asm.org)
  • To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis. (nih.gov)
  • Patients are randomized to receive IV itraconazole for 2 days, then either itraconazole daily for 5 days or amphotericin B daily for 7 days. (nih.gov)
  • This study identified correlates of ARF in amphotericin B therapy and used them to develop clinical prediction rules. (nih.gov)
  • Amphotericin B: 30 years of clinical experience. (springer.com)
  • The goal of this clinical research study is to compare the effectiveness of liposomal amphotericin B given three times per week , versus liposomal amphotericin B given once per week, versu. (bioportfolio.com)
  • The limitations of the National Committee for Clinical Laboratory Standards (NCCLS) reference methodology for detection of amphotericin B resistance are well documented, and several alternative methods have been proposed. (asm.org)
  • Vancouver, BC, November 13, 2018--(T-Net)-- iCo Therapeutics (TSXV: ICO), today announced the formation of an oral Amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David Denning. (bctechnology.com)
  • Stated Dr. Peter Hnik, Chief Medical Officer , "we look forward to working with our clinical advisors as we refine the design of mid staged clinical studies for our oral Amphotericin B candidate. (bctechnology.com)
  • type is the antifungal agent amphotericin B, which binds to a specific molecule (ergosterol) found in fungal cells. (britannica.com)
  • Amphotericin B binds to sterols, forming pores in the membrane, and causing small molecules to leak out. (sigmaaldrich.com)
  • Amphotericin binds to a lipid molecule called ergosterol, prevalent in fungus and yeast cells, as the first step in forming the complexes that make ion channels. (phys.org)
  • To treat severe fungal or yeast infections that are affecting the whole body and are potentially life-threatening, amphotericin must be given by a drip into a vein (intravenous infusion). (netdoctor.co.uk)
  • Amphotericin B liposomal must be given slowly, and the IV infusion can take 1 or more hours to complete. (rexhealth.com)
  • Some people receiving a amphotericin B liposomal injection have had a reaction to the infusion (when the medicine is injected into the vein). (rxlist.com)
  • Amphotericin B for Injection should be administered by slow intravenous infusion. (wikidoc.org)
  • Ellis D. Amphotericin B: spectrum and resistance. (springer.com)
  • Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. (healthgrades.com)
  • Aspergillosis, cryptococcus infections (e.g. meningitis) and candidiasis are treated with amphotericin B. (doctorslounge.com)
  • Amphotericin B injection is used to treat serious and potentially life-threatening fungal infections. (medlineplus.gov)
  • Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections . (healthgrades.com)
  • Ergosterol-targeting amphotericin B (AmB) is the first line of defense for life-threatening fungal infections. (sciencemag.org)
  • Domestic production of Liposomal Amphotericin B was just 62,000 vials in April, 2021 and now it is expected to cross 3.75 lakh vials in June, 2021," Mandaviya said. (moneycontrol.com)
  • The Department of Pharmaceuticals has allocated total 7,28,045 vials of Liposomal Amphotericin B to all the states and central institutions till June 17, 2021, he added. (moneycontrol.com)
  • As with other polyene antifungals, amphotericin B associates with ergosterol, a membrane chemical of fungi, forming a pore that leads to K+ leakage and fungal cell death. (doctorslounge.com)
  • They created a derivative that could bind ergosterol but could not form ion channels , and tested it against the original amphotericin. (phys.org)
  • But the ergosterol-binding, non-channel-forming derivative was almost equally potent to natural amphotericin against both of the yeast cell lines the researchers tested, once of which is highly pathogenic in humans. (phys.org)
  • The results are all consistent with the same conclusion: In contrast to half a century of prior study and the textbook-classic model, amphotericin kills yeast by simply binding ergosterol," Burke said. (phys.org)
  • Recently intravenous (IV) Liposomal amphotericin B (L-AmB) has been recommended as monotherapy therapy for refractory coccidioidal meningitis based on its advantages over (AmB-d), however, its intrathecal use has not been reported. (bioportfolio.com)
  • All 643 inpatients receiving parenteral amphotericin B therapy at one tertiary care hospital were included. (nih.gov)
  • In the subsample (N = 231), independent correlates of ARF were maximum daily amphotericin dosage, location at the time of initiation of amphotericin therapy, and concomitant use of cyclosporine. (nih.gov)
  • Correlates of ARF at the beginning and during the course of amphotericin therapy were identified and then combined to allow stratification according to ARF risk. (nih.gov)
  • In patients with frequent ABPA flares or failure of steroid tapering, inhaled amphotericin B (iAMB) is considered as alternative antifungal therapy. (hindawi.com)
  • Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. (springer.com)
  • More patients dropped out of the study when they received amphotericin B, but as none of the trials were blinded decisions on premature interruption of therapy could have been biased. (cochrane.org)
  • Amphotericin B is an antifungal drug. (adventisthealthcare.com)
  • Several FDA-approved drug labels may be available for amphotericin B. AIDS info provides the following drug label solely as an example of the labels available for amphotericin B. Inclusion or absence of a drug label on the AIDS info site does not imply endorsement or lack thereof by AIDS info . (nih.gov)
  • A drug called amphotericin (pronounced AM-foe-TARE-uh-sin) has been medicine's best defense against fungal infections since its discovery in the 1950s. (phys.org)
  • Doctors and researchers do know that amphotericin creates ion channels that permeate the cell membrane. (phys.org)
  • The membrane-active antibiotics amphotericin B and polymyxin B enhanced the action of rifampicin, rifampicin analogs, and tetracycline against macromolecular synthesis and growth of mouse L-cells, human HeLa cells, and KB cells in tissue culture. (aacrjournals.org)
  • tell your doctor and pharmacist if you are allergic to amphotericin B, any other medications, or any of the ingredients in amphotericin B injection. (medlineplus.gov)
  • Amphotericin B liposomal injection is in a class of medications called antifungals. (medlineplus.gov)
  • Amphotericin B liposomal injection comes as a suspension (liquid) to be injected intravenously (into a vein). (medlineplus.gov)
  • If you will be using amphotericin B liposomal injection at home, your healthcare provider will show you how to infuse the medication. (medlineplus.gov)
  • Ask your healthcare provider what to do if you have any problems infusing amphotericin B liposomal injection. (medlineplus.gov)
  • If your symptoms do not improve or get worse while receiving amphotericin B liposomal injection, tell your doctor. (medlineplus.gov)
  • If you become pregnant while receiving amphotericin B liposomal injection, call your doctor. (medlineplus.gov)
  • Do not breast-feed while receiving amphotericin B liposomal injection. (medlineplus.gov)
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving amphotericin B liposomal injection. (medlineplus.gov)
  • Amphotericin B liposomal injection may cause side effects. (medlineplus.gov)
  • If you are receiving amphotericin B liposomal in an outpatient clinic, call your doctor if you will miss an appointment for your amphotericin B liposomal injection. (rexhealth.com)
  • Amphotericin B liposomal is an antifungal medication that fights infections caused by fungus. (rexhealth.com)
  • Amphotericin B is an antifungal medication that fights infections caused by fungus. (wellspan.org)
  • Amphotericin B is fungistatic or fungicidal depending on the concentration obtained in body fluids and the susceptibility of the fungus. (nih.gov)
  • Amphotericin B alone is insoluble in normal saline at a pH of 7. (wikipedia.org)
  • Amphotericin B is insoluble in water at pH 6 to 7, but soluble in water at pH 2 or 11. (mpbio.com)
  • Burke's group produced a derivative of amphotericin using a molecule synthesis method Burke pioneered called iterative cross-coupling (ICC), a way of building designer molecules using simple chemical "building blocks" called MIDA boronates joined together by one simple reaction. (phys.org)